  
    
 
 
  
    A Randomized Study to Describe the Safety of an Investigational 
Quadrivalent Meningococcal Conjugate Vaccine Administered 
Concomitantly with Routine Pediatric Vaccines in Healthy Infants 
and Toddlers  
Phase III, modified double -blind, randomized, parallel -group, active -controlled, multi -center study to describe the 
safety of MenACYW conjugate vaccine when administered concomitantly with routine pediatric vaccines given to 
healthy in fants and toddlers in the United States  and Puerto Rico  
Clinical Study  Protocol  
Health Authority File Number:  BB-IND #: 14171  
WHO Universal Trial Number 
(UTN):  U1111- 1183 -6261 
Study  Code:  MET41 
Development Phase:  Phase III 
Sponsor:  Sanofi Pasteur Inc. 
Discovery Drive,  Swiftwater, PA 18370 -0187, USA 
Investigational Product:  MenACYW conjugate vaccine: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine  
Form / Route:  Liquid solution / Intramuscular  
Indication For This Study : MenACYW conjugate vaccine administered to healthy infants  and toddlers  
at 2, 4, 6, and 12 months of age  
Manufacturer:  Same as Sponsor  
Coordinating Investigator  To be determined  
Sponsor’s Responsible Medical Officer:  
Pharmaco vigilance Global Safety 
Expert : 
Regional Clinical Trial Manager:  
Version and Date of the Protocol:  Version 4.0 dated 29 May 2019 
Information contained in this publication is the property of Sanofi Pasteur  and is confidential. This information may not be 
disclosed to third parties without written authorization from Sanofi Pasteur . This document may not be reproduced, stored in a 
retrieval system, or transmitted in any form or by any means–electronic, mechanical recording, or otherwise –without prior 
authorization from Sanofi Pasteur . This document must be returned to Sanofi Pasteur  upon request.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 1 of 90[STUDY_ID_REMOVED]

   
    
 
 
  
    History of Protocol Versions  
Previous versions of the protocol 
Version  Date Comments  
1.0 19 October 2017  Internal version not submitted  
2.0 4 May 2018  Internal version not submitted  
3.0 9 May 2018  First version of the Protocol  
 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 2 of 90
   
    
 
 
  
    Table of Contents  
History of Protocol Versions ........................................................................................................... 2  
List of Tables  .................................................................................................................................... 8  
Synopsis  ............................................................................................................................................ 9  
Table of Study Procedures  ............................................................................................................ 19  
List of Abbreviations  ..................................................................................................................... 22  
1 Introduction ..................................................................................................................... 25  
1.1 Background ..................................................................................................................... 25  
1.2 Background of the Investigational Product ..................................................................... 26  
1.2.1  Clinical  ......................................................................................................................... 26  
1.2.1.1  Study MET3 9 (Phase II)  ............................................................................................ 26  
1.2.1.2  Study MET54 (Phase II) ............................................................................................ 27  
1.3 Potential Benefits and Risks ........................................................................................... 29  
1.3.1  Potential Benefits to Subjects  ....................................................................................... 29  
1.3.2  Potential Risks to Subjects ........................................................................................... 29  
1.4 Rationale for the Study ................................................................................................... 30  
2 Study Objective  ............................................................................................................... 31  
3 Investigators and Study Organization ........................................................................... 31  
4 Independent Ethics Committee / Institutional Review Board  .................................... 31  
5 Investigational Plan  ......................................................................................................... 32  
5.1 Description of the Overall Study Design and Plan ......................................................... 32  
5.1.1  Study Design ................................................................................................................ 32  
5.1.2  Justification of the Study Design .................................................................................. 33  
5.1.3  Study Plan ..................................................................................................................... 34  
5.1.4  Visit Procedures  ............................................................................................................ 35  
5.1.5  Planned Study Calendar ............................................................................................... 41  
5.1.6  Early Safety Data Review ............................................................................................. 41 
5.2 Enrollment and Retention of Study Population .............................................................. 42  
5.2.1  Recruitment Procedures  ................................................................................................ 42  
5.2.2  Informed Consent Procedures ...................................................................................... 42  
5.2.3  Screening Criteria  ......................................................................................................... 42  
5.2.4  Inclusion Criteria  .......................................................................................................... 42  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 3 of 90
   
    
 
 
  
    5.2.5  Exclusion Criteria  ......................................................................................................... 43  
5.2.6  Medical History  ............................................................................................................ 44  
5.2.7  Contraindications for Subsequent Vaccinations ........................................................... 45  
5.2.7.1  Temporary Contraindications ..................................................................................... 45  
5.2.7.2  Definitive Contraindications  ...................................................................................... 45  
5.2.7.3  Warnings and Precautions to Vaccination  ................................................................. 47  
5.2.8  Conditions for Withdrawal ........................................................................................... 47  
5.2.9  Lost to Follow-up Procedures....................................................................................... 48  
5.2.10  Classification of Subjects Who Discontinue the Study ................................................ 48  
5.2.11  Follow-up of Discontinuations ..................................................................................... 49  
5.3 Safety Emergency Call  ................................................................................................... 49  
5.4 Modification of the Study and Protocol .......................................................................... 49  
5.5 Interruption of the Study ................................................................................................. 50  
6 Vaccines Administered  ................................................................................................... 50  
6.1 Identity of the Investigational Products .......................................................................... 50  
6.1.1  Identity of Study Product .............................................................................................. 50  
6.1.1.1  Composition  ............................................................................................................... 50  
6.1.1.2  Preparation and Administration  ................................................................................. 51  
6.1.1.3  Dose Selection and Timing ........................................................................................ 51  
6.1.2  Identity of Control Product ........................................................................................... 51  
6.1.2.1  Composition  ............................................................................................................... 52  
6.1.2.2  Prepar ation and Administration  ................................................................................. 52  
6.1.2.3  Dose Selection and Timing ........................................................................................ 52  
6.2 Identity of Other Products ............................................................................................... 52  
6.2.1  Identity of Other Product 1 ........................................................................................... 52  
6.2.1.1  Composition  ............................................................................................................... 52  
6.2.1.2  Preparation and Administration  ................................................................................. 53  
6.2.1.3  Dose Selection and Timing ........................................................................................ 53  
6.2.2  Identity of Other Product 2 ........................................................................................... 53  
6.2.2.1  Composition  ............................................................................................................... 54  
6.2.2.2  Preparation and Administration  ................................................................................. 54  
6.2.2.3  Dose Selection and Timing ........................................................................................ 54  
6.2.3  Identity of Other Product 3 ........................................................................................... 54  
6.2.3.1  Composition  ............................................................................................................... 54  
6.2.3.2  Preparation and Administration  ................................................................................. 55  
6.2.3.3  Dose Selection and Timing ........................................................................................ 55  
6.2.4  Identity of Other Product 4 ........................................................................................... 55  
6.2.4.1  Composition  ............................................................................................................... 55  
6.2.4.2  Preparation and Administration  ................................................................................. 55  
6.2.4.3  Dose Selection and Timing ........................................................................................ 56  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 4 of 90
   
    
 
 
  
    6.2.5  Identity of Other Product 5 ........................................................................................... 56  
6.2.5.1  Composition  ............................................................................................................... 56  
6.2.5.2  Preparation and Administration  ................................................................................. 56  
6.2.5.3  Dose Selection and Timing ........................................................................................ 57  
6.2.6  Identity of Other Product 6 ........................................................................................... 57  
6.2.6.1  Composition  ............................................................................................................... 57  
6.2.6.2  Preparation and Administration  ................................................................................. 57  
6.2.6.3  Dose Selection and Timing ........................................................................................ 57  
6.3 Product Logistics ............................................................................................................ 58  
6.3.1  Labeling and Packaging ............................................................................................... 58  
6.3.2  Product Shipment, Storage, and Accountability ........................................................... 58  
6.3.2.1  Product Shipment ....................................................................................................... 58  
6.3.2.2  Product Storage .......................................................................................................... 58  
6.3.2.3  Product Accountability ............................................................................................... 59  
6.3.3  Replacement Doses ....................................................................................................... 59 
6.3.4  Disposal of Unused Products ........................................................................................ 59  
6.3.5  Recall of Products ......................................................................................................... 59  
6.4 Blinding and Code-breaking Procedures ........................................................................ 59  
6.5 Randomization and Allocation Procedures ..................................................................... 60  
6.6 Treatment Compliance  .................................................................................................... 60  
6.7 Concomitant Medications and Other Therapies  ............................................................. 61  
7 Management of Samples ................................................................................................. 62  
8 Clinical Supplies  .............................................................................................................. 62  
9 Endpoints and Assessment Methods ............................................................................. 63  
9.1 Observational Endpoints and Assessment Methods ....................................................... 63  
9.1.1  Safety  ............................................................................................................................ 63  
9.1.1.1  Safety Defin itions  ....................................................................................................... 63  
9.1.1.2  Safety Endpoints ........................................................................................................ 66  
9.1.1.3  Safety Assessment Methods ....................................................................................... 66  
9.1.1.3.1  Immediate Post -vaccination Observation Period ..................................................... 67  
9.1.1.3.2  Reactogenicity (Solicited Reactions From Day  0 to Day 7 After Each 
Vaccination)  ............................................................................................................. 67  
9.1.1.3.3  Unsolici ted Adverse Events  ..................................................................................... 70  
9.1.1.3.4  Adverse Events of Special Interest  .......................................................................... 71  
9.1.1.3.5  Medically -Attended Adverse Events  ....................................................................... 72  
9.1.1.3.6  Assessment of Causality  .......................................................................................... 72  
9.2 Immunogenicity .............................................................................................................. 72  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 5 of 90
   
    
 
 
  
    9.3 Efficacy  ........................................................................................................................... 72  
10 Reporting of Serious Adverse Events ............................................................................ 73  
10.1  Initial Reporting by the Investigator  ............................................................................... 73  
10.2  Follow-up Reporting by the Investigator ........................................................................ 74  
10.3  Reporting of SAEs Occurring After a Subject Has Completed the Study ...................... 74  
10.4  Assessment of Causality  ................................................................................................. 74  
10.5  Reporting SAEs to Health Authorities and IECs / IRBs ................................................. 74  
11 Data Collection and Management ................................................................................. 75  
11.1  Data Collection and CRB Completion ............................................................................ 75  
11.2  Data Management  ........................................................................................................... 76  
11.3  Data Review  .................................................................................................................... 76  
12 Statistical Methods and Determination of Sample Size  ............................................... 76  
12.1  Statistical Methods  .......................................................................................................... 76  
12.1.1  Hypotheses and Statistical Methods for the Objectives ............................................... 77  
12.1.1.1  Hypotheses ................................................................................................................. 77  
12.1.1.2  Statistical Methods  ..................................................................................................... 77  
12.2  Analysis Sets ................................................................................................................... 77  
12.2.1  Full An alysis Set  ........................................................................................................... 77  
12.2.2  Safety Analysis Set  ....................................................................................................... 78  
12.2.2.1  Overall Safety Analysis Set for Any Dose ................................................................. 78  
12.2.2.2  Safety Analysis Set for Vaccination at 2 Months of Age .......................................... 78  
12.2.2.3  Safety Analysis Set for Vaccination at 4 Months of Age  .......................................... 78  
12.2.2.4  Safety Analysis Set for Vaccination at 6 Months of Age .......................................... 78  
12.2.2.5  Safety Analysis Set for Vaccination at 12 Months of Age ........................................ 79  
12.2.2.6  Safety Analysis Set for all 4 -dose Vaccinations ........................................................ 79  
12.2.3  Per-Protocol Analysis Set ............................................................................................. 79  
12.2.4  Populations Used in Analyses ...................................................................................... 79  
12.3  Handling of Missing Data and Outliers .......................................................................... 79  
12.3.1  Safety  ............................................................................................................................ 79  
12.3.2  Immunogenicity ............................................................................................................ 79  
12.3.3  Efficacy  ......................................................................................................................... 79  
12.4  Interim / Preliminary Analysis  ........................................................................................ 80  
12.5  Determination of Sample Size and Power Calculation  ................................................... 80  
13 Ethical and Legal Issues and Investigator / Sponsor Responsibilities ........................ 80  
13.1  Ethical Conduct of the Study / Good Clinical Practice ................................................... 80  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 6 of 90
   
    
 
 
  
    13.2  Source Data and Source Documents ............................................................................... 80  
13.3  Confidentiality of Data, Data Protection and Access to Subject Records ...................... 81  
13.4  Monitoring, Auditing, and Archiving ............................................................................. 81  
13.4.1  Monitoring .................................................................................................................... 81  
13.4.2  Audits and Inspections ................................................................................................. 82  
13.4.3  Archiving ...................................................................................................................... 82  
13.5  Financial Contract and Insurance Coverage ................................................................... 83  
13.6  Stipends for Participation  ................................................................................................ 83  
13.7  Publication Policy  ........................................................................................................... 83  
14 Reference List  .................................................................................................................. 84  
15 Signature Pag e ................................................................................................................. 89  
 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 7 of 90
   
    
 
 
  
    List of Tables  
Table 5.1: Vaccination schedule......................................................................................................35  
Table 9.1: Solicited injection site reactions: terminology, definitions, and intensity scales  ...........68  
Table 9.2: Solicited systemic reactions: terminology, definitions, and intensity scales .................69  
 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 8 of 90
   
    
 
 
  
    Synopsis 
Company:  Sanofi Pasteur  
Investigational Product:  MenACYW conjugate vaccine 
Active Substances:  Capsular polysaccharide from meningococcal serogroups A, C, Y, and W 
conjugated to tetanus toxoid  
  
Title of the Trial:  A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly 
with Routine Pediatric Vaccines in Healthy Infants and Toddlers  
Development Phase:  Phase III  
Coordinating Investigator:  To be determined  
Trial Centers:  This will be a multi -center study conducted at approximately 65 sites in the 
United States  and Puerto Rico . 
Investigators and sites are listed in the “List of Investigators and Centers 
Involved in the Trial” d ocument.  
Planned Trial Period:  3Q 2018 to 2 Q 2021  
Trial Design and Methodology:  A Phase III, modified double -blind, randomized, parallel -group, active -
controlled, multi- center study to describe the safety of MenACYW conjugate 
vaccine when administered concomitantly with routine pediatric vaccines given 
to healthy infants and toddlers in the United States  and Puerto Rico . 
Approximately 3080 healthy infants aged ≥ 42 to ≤ 89 days will be randomized  
in 3:1 ratio to the following 2  groups: 
Group 1:  MenACYW conjugate vaccine + routine pediatric vaccines  
Group 2:  MENVEO® + routine pediatric v accines  
All subjects will receive a dose of either MenACYW conjugate vaccine or 
MENVEO® with the following routine pediatric vaccines: Pentacel® (DTaP -
IPV//Hib) at 2, 4, and 6 months  of age *; PREVNAR  13® (pneumococcal 13 -
valent conjugate vaccine; PCV13) at 2, 4, 6, and 12  months  of age ; RotaTeq® 
(rotavirus vaccine ) at 2, 4, and 6 months  of age ; ENGERIX-B® (hepatitis B 
vaccine) at 2 and 6  months  of age†; and M -M-R® II (measles, mumps, and 
rubella vaccine) and V ARIVAX® (varicella vaccine) at 12  months  of age .  
*All subjects will complete the last study visit at 13 to 14 months of age. For 
all subjects, the 4th dose of Pentacel® should be  administered  by site personnel  
at 15 to 18 months of age  as per standard practice. The 4th dose of Pentacel® 
will be provid ed by the Sponsor for completion of the DTaP series with 
vaccine from the same manufacturer, to ensure compliance with the Advisory 
Committee on Immunization Practices ( ACIP ) recommendation.  
† First dose of hepatitis B vaccine must be given at least 28 day s prior to study 
enrollment.  
 Study vaccines will be administered as part of the study on the following schedules:  
Group  1: MenACYW conjugate vaccine and routine pediatric vaccines at 2, 4, 
6, and 12  months of age  
Group  2: MENVEO
® and routine pediatric vaccines at 2, 4, 6, and 12  months 
of age  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 9 of 90
   
    
 
 
  
     Saf
ety data will be collected as follows: Immediate unsolicited systemic 
adverse events ( AEs) will be collected within 30 minutes after each 
vaccination. Solicited AE information will be collected from D0 to D07 after 
each vaccination; unsolicited AE information will be collected from D0 after 
each vaccination  to the next study visit ; serious adve rse event (SAE) 
information (including adverse events of special interest [AESIs]) and medically -attended adverse events (MAAEs) will be collected throughout the 
study from Visit 1 ( day o f first vaccination) until the end of the 6- month follow 
up period af ter the last vaccination.  
Early Safety Data Review:  No Early Safety Data Review (i.e., no early safety review[s] of preliminary safety data occurring at pre -determined milestones defined in the protocol, with 
pause in enrollment) is planned for this trial as MenACYW conjugate vaccine has been previously adm inistered to infants, toddlers, and adults with an 
acceptable safety profile and no safety concerns have been identified in the 
clinical trials completed so far. There will be an internal team at the level of the 
Sponsor (Safety Management Team, [SMT]), wh ich will review the data being 
generated from all the ongoing studies with MenACYW conjugate vaccine at 
regular intervals for any new safety signals or safety concerns. The SMT is 
empowered to recommend a pause in both recruitment and/or further 
vaccinatio n while it investigates any potential signal or concern.  
This trial may be interrupted at any time if new data about the investigational 
product become available, and/or on advice of the Sponsor, the Independent 
Ethics Committees (IECs) / Institutional Rev iew Boards (IRBs), or the 
governing regulatory authorities in the US where the trial is taking place.  
If the trial is prematurely terminated or suspended, the Sponsor will promptly inform the Investigators, the IECs/IRBs, and the regulatory authorities of the 
reason for termination or suspension. If the trial is prematurely terminated for any reason, the Investigator will promptly inform the subjects’ parents / guardians and should assure appropriate therapy  (if needed)  and follow -up. 
Objective:  To describe the safety profile of MenACYW conjugate vaccine and 
MENVEO® when administered concomitantly with routine pediatric vaccines 
in healthy infants and toddlers.  
Endpoints:  The following endpoints will be used for all subjects for the evaluation of  
safety:  
• Occurrence, nature (Medical Dictionary for Regulatory Activities [MedDRA] preferred term), duration, intensity, and relationship to vaccination, and whether the event led to early termination from the 
study, of any unsolicited systemic AEs reported in the 30  minutes after 
each vaccination.  
• Occurrence, time of onset, number of days of occurrence, intensity, 
action taken, and whether the reaction led to early termination from the 
study, of solicited (prelisted in the subject’s diary card and e lectronic case 
report book  [CRB]) injection site reactions occurring up to D07 after 
each vaccination.  
 • Occurrence, time of onset, number of days of occurrence, intensity, 
action taken, and whether the reaction led to early termination from the 
study, of solicited (prelisted in the subject’s diary card and CRB ) 
systemic reactions occurring up to D07 after each vaccination.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 10 of 90
   
    
 
 
  
     • Occ
urrence, nature (MedDRA preferred term), time of onset, duration, 
intensity, action taken, relationship to vaccination , and  whether the event 
led to early termination from the study, of unsolicited AEs up to D30 
after each vaccination.  
• Occurrence, nature (MedDRA preferred term), time of onset, duration, 
seriousness criteria, relationship to vaccination, outcome, and whether the  
event led to early termination from the study, of SAEs (including AESIs) 
throughout the trial from Visit 1 to the 6-month follow -up contact after 
the last vaccination.  
• Occurrence, nature (MedDRA preferred term), time of onset, duration, 
intensity, action taken, relationship to vaccination , and  whether the event 
led to early termination from the study for MAAEs throughout the trial, 
from Visit 1 to the 6-month follow -up contact after the last vaccination. 
Planned Sample Size:  Approximately 3080  subjects are planned to be enrolled:  
Group 1 (MenACYW conjugate vaccine):  n = 2310 
Group 2 ( MENVEO®):    n = 770  
Schedule of Study Procedures : Vaccination  
All subjects will receive a dose of either MenACYW conjugate vaccine or 
MENVEO® with routine pediatric vaccines at 2, 4, 6, and 12  months of age. 
All subjects will receive the routine pediatric vaccines as per  the approved 
ACIP recommended schedules: Pentacel® at 2, 4, and 6 months  of age *; 
PREVNAR  13® at 2, 4, 6, and 12 months  of ag e; RotaTeq® at 2, 4, and 
6 months  of age ; ENGERIX -B® at 2 and 6  months  of age†; and M-M-R® II 
and VARIVAX® at 12  months  of age . 
 Study vaccines will be administered according to the following schedules:  
Group  1: MenACYW conjugate vaccine and routine pediatric vaccines will 
be administered at 2, 4, 6, and 12  months of age.  
Group  2: MENVEO® vaccine and routine pediatric vaccines will be 
administered at 2, 4, 6, and 12  months of age.  
* All subjects will complete the last study visit at 13 to 14 months of  age. For 
all subjects, the 4th dose of Pentacel® should be  administered  by site personnel  
at 15 to 18 months of age  as per standard practice.  The 4th dose of Pentacel® 
will be provided by the Sponsor for completion of the DTaP series with vaccine from the same manufacturer, to ensure compliance with the ACIP 
recommendation.  
† First dose of hepatitis B vaccine must be given at least 28 days prior to study 
enrollment.  
Blood sampling  
No blood samples will be collected  as this is a safety study.  
 Collection of safety data  
• All subjects will be followed for safety from Visit  1 to 6 months after the 
last vaccinations at 12 months  of age . 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 11 of 90
   
    
 
 
  
     • All subjects will be observed for 30 minutes after each vaccination, and 
any unsolicited systemic AEs occurring during that time will be recorded 
as immediate unsolicited systemic AEs in the CRB. 
• The subject’s parent / guardian will record information in a diary card about solicited reactions from D0 to D07 after each vaccination and unsolicited AEs from D0 after each vaccinati on to the next study visit . 
 • SAEs (including AESIs) and MAAEs will be recorded throughout the study. The subject’s parent / guardian will record information in a diary 
card about SAEs and MAAEs from Visit 1 to Visit 2, from Visit 2 to 
Visit  3, from Visit 3 to Visit 4,  and from Visit  4 to Visit 5 . SAEs and 
MAAEs will also be recorded in a memory aid from D31 after the last 
vaccination visit until the 6 -month follow up phone call.  
 • The subject’s parent/ guardian will be asked to notify the site 
immediately about any potential SAEs at any time during the trial.  
• Staff will contact the subjects’ parent/ guardian by telephone 8 days 
(+2 days) after each vaccination visit to identify the occurrence of any 
SAEs (including AESIs) not yet reported and to remind them  to complete 
the diary card after each vaccination visit and to bring it back at the 
subsequent visit.  
• The completed diary cards will each be collected and reviewed with the 
subject’s parent/ guardian at the subsequent visit.  
• Staff will contact the subject s’ parent/ guardian by telephone within 
14 days before Visit 4 to remind them about the forthcoming study visit. 
If the subject ’s participation  in the study  is discontinued, the information 
recorded on the diary card will be reviewed at this time and  the subject’s 
parent / guardian will be asked to mail the diary  card to the site . 
• Staff will contact the subjects’ parent/ guardian by telephone at 6  months 
(+30 days) after the last vaccination visit to review the memory aid and identify the occurrence of any  MAAEs, as well as SAEs (including 
AESIs) that have not been reported.  
Duration of Participation in the Trial:  The duration of each subject’s participation in the trial will be approximately 16 months, which will include a safety follow -up contact at 6  months after the 
final vaccination.  
Investigational Product:  MenACYW conjugate vaccine: Meningococcal Polysaccharide 
(Serogroups  A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (Sanofi 
Pasteur Inc., Swiftwater, PA, USA)  
 Form:  Liquid solution  
 Composition:  Each 0.5  milliliter (mL) dose of MenACYW conjugate vaccine  is formulated 
in sodium acetate buffered saline solution to contain the following ingredients:  
Meningococcal capsular polysaccharides:  
Serogroup A  ..................................................................  10 micrograms (µg)  
Serogroup C  .........................................................................................  10 µg 
Serogroup Y  .........................................................................................  10 µg 
Serogroup W  ........................................................................................  10 µg 
Tetanus toxoid protein carrier  ....................................  approximately 55  µg* 
* ....... Tetanus toxoid  protein quantity is approximate and dependent on the 
polysaccharide -to-protein ratio for the conjugates used in each formulation.  
 Route:  Intramuscular (IM)  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 12 of 90
   
    
 
 
  
     Batc
h Number:  To be determined  
Control Product:  MENVEO®: Meningococcal (Groups A, C, Y and W -135) Oligosaccharide 
Diphtheria CRM 197 Conjugate Vaccine (GSK Vaccines, Srl, Bellaria- Rosia 
53018, Sovicille [SI], Italy)  
 Form:  Lyophilized powder and liquid components are combined to produce a 
Solution for Intramuscular Injection  
 Composition:  Each 0.5 mL dose of vaccine contain s the following active ingredients:  
MenA oligosaccharide  ...........................................................................  10 mcg 
MenC oligosaccharide  .............................................................................  5 mcg 
MenY oligosaccharide  .............................................................................  5 mcg 
MenW -135 oligosaccharide  .....................................................................  5 mcg 
CRM 197 protein  .......................................................................  32.7 to 64.1  mcg 
Other ingredients per 0.5 mL dose: residual f ormaldehyde ≤  0.30 mcg. 
 Route:  IM 
 Batch Number:  To be determined  
Other Product 1:  Pentacel®: (Diphtheria and Tetanus Toxoids and Acellular Pertussis 
Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine (Sanofi Pasteur Ltd, Toronto, Ontario, Canada)  
 Form:  Liquid DTaP -IPV used to reconstitute lyophilized  ActHIB® 
 Composition:  Each 0.5 mL dose contains:  
Diphtheria toxoid  ................................................  15 Limit of Flocculation (Lf)  
Tetanus toxoid  ............................................................................................ 5 Lf 
Acellular pertussis antigens:  
  Pertussis toxin (PT)  ................................................................................  20 µg 
  Filamentous hemagglutinin (FHA)  ........................................................ 20 µg 
  Pertactin (PRN)  ........................................................................................  3 µg 
  Fimbriae Types 2 and 3 (FIM)  ................................................................. 5 µg 
Inactivated polioviruses:  
  Type 1 (Mahoney) ...................................................  40 D- antigen units (DU)  
  Type 2 (MEF -1) ...................................................................................... 8 DU  
  Type 3 (Saukett)  ...................................................................................  32 DU  
 H. influenzae  type b (PRP) ......................................................................  10 µg 
Tetanus toxoid (PRP -T) ...........................................................................  24 µg 
 Excipients:  
Aluminum phosphate (0.33 mg aluminum) (adjuvant)  ..........................  1.5 mg 
Polysorbate 80  ........  approximately 10 parts per million (ppm) by calculation  
Sucrose  ................................................................................................ 42.5 mg  
Residual formaldehyde  ...........................................................................  ≤ 5 µg 
Residual glutaraldehyde  ........................................................................  < 50 ng  
Residual bovine serum albumin .............................................................  ≤ 50ng 
2-phenoxyethanol  ................................................................ 3.3 mg (0.6% v/v)  
Neom ycin .............................................................................  < 4 picogram (pg) 
Polymyxin B sulfate  ...............................................................................  < 4 pg 
 Route:  IM 
 Batch Number:  To be determined  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 13 of 90
   
    
 
 
  
    Othe
r Product 2:  PREVNAR 13®: Pneumococcal 13 -valent Conjugate Vaccine (Diphtheria 
CRM 197 Protein) (Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc, 
Philadelphia, PA, USA)  
 Form:  Suspension for injection  
 Composition:  Each 0.5 mL dose of the vaccine is formulated to contain  
Streptococcus pneumoniae  serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 
19F, 23F saccharides  .......................................... approximately 2.2 μg of each  
6B saccharides  ........................................................................................  4.4 μg  
Excipients:  
CRM 197 carrier protein  .............................................................................  34 μg 
Polysorbate 80 .......................................................................................  100 μg 
Succinate buffer  .....................................................................................  295 μg 
Aluminum as aluminum phosphate adjuvant  .........................................  125 μg 
 Route:  IM 
 Batch Number:  To be determined  
Other Product 3:  RotaTeq®: (Rotavirus Vaccine, Live, Oral, Pentavalent) (Merck Sharp & 
Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, 
USA)  
 Form:  Oral solution  
 Composition:  Each 2 mL dose contains the following 5 live reassortant rotaviruses:  
G1 serotype  ........................................................ 2.2 x 106 infectious units (IU)  
G2 serotype  ....................................................................................  2.8 x 106 IU 
G3 serotype  ....................................................................................  2.2 x 106 IU 
G4 serotype  .....................................................................................  2.0 x 106IU 
P1A(8) ............................................................................................  2.3 x 106IU 
The reassortants are suspended in a buffered stabilizer sol ution.  
Each 2 mL vaccine dose also contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell 
culture media, and trace amounts of fetal bovine serum.  
 Route:  Oral (PO)  
 Batch Number:  To be determined  
Other Product 4:  ENGERIX -B®: (Hepatitis B Vaccine [Recombinant]) (GlaxoSmithKline 
Biologicals 441 Rixensart, Belgium)  
 Form:  Suspension for injection  
 Composition:  Each 0.5 mL pediatric/adolescent dose contains 10 µg of hepatitis B virus 
surface antigen  (HBsAg) adsorbed on 0.25 mg aluminum as aluminum 
hydroxide.  
Excipients:  
Sodium chloride  ..................................................................................  9 mg/mL  
Disodium phosphate dihydrate  ...................................................... 0.98 mg/mL  
Sodium dihydrogen phosphate dihydrate  .......................................  0.71 mg/mL  
 Route:  IM 
 Batch Number:  To be determined  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 14 of 90
   
    
 
 
  
    Othe
r Product 5:  M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live) (Merck Sharp 
& Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, 
USA)  
 Form:  Lyophilized live virus vaccine  
 Composition:  Each 0.5 mL dose contains live, attenuated virus:  
Measles virus (derived from Ender’s Edmonston strain) propagated in chick 
embryo cell culture  ................................................  not less than 1000 TCID 50* 
Mumps virus (Jeryl Lynn™ [B level] strain) propagated in chick embryo  
cell culture  .......................................................... not less than 12,500 TCID 50* 
Rubella virus (Wistar RA 27/3 strain) propagated in WI -38 human diploid 
lung fibroblasts  ...................................................... not less than 1000 TCID 50* 
*TCID 50 = tissue culture infectious doses 50%  
Each 0.5 mL dose is calculated to contain sorbitol (14.5 mg), sodium 
phosphate, sucrose (1.9 mg), sodium chloride, hydrolyzed gelatin (14.5  mg), 
recombinant human albumin (≤  0.3 mg), fetal bovine serum (<  1 ppm), other 
buffer and media ingredients and approximately 25 µg of neomycin.  
 Route:  Subcutaneous (SC)  
 Batch Number:  To be determined  
Other Product 6:  VARIVAX®: Varicella Virus Vaccine Live (Merck Sharp & Dohme Corp., a 
subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA)  
 Form:  Suspension for injection supplied as lyophilized vaccine to be reconstituted 
using the accompanying sterile diluent  
 Composition:  Each approximately 0.5 mL dose contains:  
Oka/Merck varicella virus  ...............  at least 1350 plaque -forming units (PFU)  
Excipients:  
Sucrose  ...................................................................................................  25 mg  
Hydrolyzed gelatin  ...............................................................................  12.5 mg  
Sodium chloride  .....................................................................................  3.2 mg 
Monosodium L -glutamate ......................................................................  0.5 mg 
Sodium phosphate dibasic  ...................................................................  0.45 mg  
Potassium phosphate monobasic  .........................................................  0.08 mg 
Potassium chloride  ...............................................................................  0.08 mg 
The vaccine contains residual components of MRC -5 cells including DNA 
and protein and trace quantities of sodium phosphate monobasic, EDTA, neomycin, and fetal bovine serum. The vaccine contains no preservative.  
 Route:  SC 
 Batch Number:  To be determined  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 15 of 90
   
    
 
 
  
    Incl
usion Criteria:  An individual must fulfill all of the following criteria in order to be eligible 
for study enrollment: 
1) Aged ≥ 42 to ≤ 89 days on the day of the first study visit.  
2) Healthy infants as determined by medical history, physical examination 
and judgment of the Investigator . 
3) Informed consent form has been signed and dated by the parent(s) or guardian and by an independent witness if required by local regulations.  
4) Subject an d parent/guardian are able to attend all scheduled visits and to 
comply with all trial procedures.  
5) Infants who received the first dose of hepatitis B vaccine at least 28 days 
before the first study visit.  
Exclusion Criteria:  An individual fulfilling any of the following criteria is to be excluded from 
study enrollment:  
1) Participation at the time of study enrollment or in the 4 weeks preceding the first trial vaccination or planned participation during the present trial period in another clinical trial inv estigating a vaccine, drug, medical 
device, or medical procedure.  
 2) Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned receipt of any vaccine in the 4 weeks before and / or following 
any trial vaccination except for influenza vaccination, which may be 
received at least 2 weeks before or 2 weeks after any study vaccination. This exception includes monovalent pandemic influenza vaccines and 
multivalent influenza vaccines.  
 3) Previous vaccination against meningococcal disease with either the trial 
vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or 
conjugate meningococcal vaccine containing serogroups A, C, Y, or W; 
or meningococcal B serogroup- containing vaccine).  
 4) Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, 
hepatitis A, measles,  mumps, rubella, varicella; and  Haemophilus 
influenzae  type b, Streptococcus pneumoniae , and /or rotavirus infection 
or disease  
5) Receipt of more than 1 previous dose of hepatitis B vaccine.  
6) Receipt of immune globulins, blood or blood -derived products since 
birth.  
 7) Known or suspected congenital or acquired immunodeficiency; or receipt 
of immunosuppressive therapy, such as anti -cancer chemotherapy or 
radiation therapy; or long -term systemic corticosteroid therapy 
(prednisone or equivalent for more than 2 consecutive weeks) since birth.  
8) Family history of congenital or hereditary immunodeficiency until the 
immune competence of the potential vaccine recipient is demonstrated.  
9) Individuals with bl ood dyscrasias, leukemia, lymphoma of any type, or 
other malignant neoplasms affecting the bone marrow or lymphatic systems. 
10) Individuals with active tuberculosis  
11) History of any Neisseria meningitidis  infection, confirmed either 
clinically, serologically, or microbiologically.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 16 of 90
   
    
 
 
  
     12) Hi
story of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, 
hepatitis A, measles, mumps, rubella, varicella, Haemophilus influenzae  
type b, Streptococcus pneumoniae , and /or rotavirus infection/disease.  
13) At high risk for meningococcal infection during the trial (specifically, but 
not limited to, subjects with persistent complement deficiency, with anatomic or functional asplenia, or subjects traveling to countries with high endemic or epidemic disease).  
 14) History of intussusception.  
15) History of any neurologic disorders, including seizures and progressive neurologic disorders.  
16) History of Guillain -Barré syndrome.  
17) Known systemic hypersensitivity to any of the vaccine components or to latex, or history of a life -threatenin g reaction to the vaccine(s) used in the 
trial or to a vaccine containing any of the same substances, including 
neomycin, gelatin, and yeast.  
 18) Verbal report of thrombocytopenia contraindicating intramuscular vaccination in the Investigator’s opinion.  
 19) Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding 
inclusion, contraindicating intramuscular vaccination in the Investigator’s 
opinion  
 20) Chronic illness (including, but not limited to, cardiac disorders, 
congenital heart disease, chronic lung disease, renal disorders, auto -
immune disorders, diabetes, psychomotor diseases, and known congenital 
or genetic diseases) that, in the opinion of the Investigator, i s at a stage 
where it might interfere with trial conduct or completion  
 21) Any condition which, in the opinion of the Investigator, might interfere 
with the evaluation of the study objectives  
 22) Moderate or severe acute illness/infection (according to Investigator 
judgment) on the day of vaccination or febrile illness (temperature 
≥ 38°C  [≥ 100.4°F ]). A prospective subject should not be included in the 
study until the condition has resolved or the  febrile event has subsided. 
 23) Identified as a natural or adopted child of the Investigator or employee 
with direct involvement in the proposed study.  
Statistical Methods:  Safety  / Reactogenicity 
The Safety Analysis Set (SafAS) is defined as those subjects who have received at least 1 dose of the study vaccine and have any safety data 
available. All subjects will have their safety analyzed for each dose according 
to the vaccine they actually received at that dose. Safety analysis after all of 
the 4 -dose vaccinations will be conducted as well. If the vaccine received by a 
subject does not correspond to any study group, the subject will be excluded 
from the SafAS. The corresponding safety data will be presented in separate 
listings.  
Safety analysis will include but not be limited to the following:  
The number and percentage of subjects reporting any solicited injection  site 
reactions and solicited systemic reactions occurring from D0 to D07 after each vaccination will be summarized by study group for intensity, time of onset 
period, days of occurrence, and action taken.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 17 of 90
   
    
 
 
  
     Imm
ediate unsolicited systemic AEs and unsolicited AEs occurring up to 
D30 after each vaccination will be summarized.  
The number and percentage of subjects reporting any unsolicited non -serious 
AEs will be summarized by study group, intensity, time of onset period, 
duration, and by MedDRA preferred term and system organ class (SOC), as 
well as by relationship to the study vaccine.  
 The number and percentage of subjects reporting at least one of any MAAE s 
will be summarized throughout the study.  
The number and percentage of subjects reporting at least one of any SAEs will be summarized by study group, seriousness criterion, outcome, and by 
MedDRA preferred term and SOC, as well as by relationship to the study 
vaccine.  
The number and percentage of subjects reporting at least one of any AESIs 
will be summarized throughout the study.  
Exact (Clopper -Pearson) 2 -sided 95% confidence intervals ( CIs) will be 
calculated for the percentages.  
Sample Size Calculation  
The sample size of this study was chosen to provide safety data; it is not intended for the purposes of hypothesis testing. No formal sample size calculation is performed.  
Though there ar e no statistically powered hypotheses, the overall study cohort 
of 3080 subjects will provide a probability of approximately 95% of observing 
any AE with a true incidence of 0.15%. In the treatment arm with 
2310  subjects, there is a probability of approximately 95% of observing any 
AE with a true incidence of 0.2%.  
 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 18 of 90
   
    
 
 
  
    Table of Study Procedures  
Phase III Study, 5 Visits, 4 Vaccination visits, 6 Telephone calls, 18 Vaccinations, 16 -Months’ Duration Per Subject  
Visit/Contact Visit 1  Telephone 
Call  
(TC) 1 Visit 2  TC2  Visit 3*  TC3  TC4  Visit 4†  TC5 Visit 5  TC6 
Follow -up 
contact 
Approximate a ge of s ubject  2 months  
(42 to 
89 days)  - 4 months  - 6 months (164 
to 224 days)  -  12 months  - 13 months  18 months  
Trial timelines (days) D0 Visit 1 + 
8 days Visit 1 + 
60 days Visit 2 + 
8 days Visit 2 + 
60 days Visit 3 + 
8 days Visit 4  
-14 days  Visit 4 + 
8 days Visit 4 + 
30 days Visit 4 + 
180 days 
Time windows (days)   +2 days  + 14 days  +2 days  + 14 days  +2 days    +2 days  +21 days +30 days  
Informed consent form signed and 
dated  X           
Inclusion/exclusion criteria  X           
Collection of demographic data  X           
Medical history  X           
Physical examination  X       X    
Temperature measurement X  X  X   X    
Contact IRT system for randomization / allocation of subject number / vaccine group assignment  
X           
Review of warnings and precautions to vaccinations  X  X  X   X    
Review of contraindications to subsequent vaccinations and conditions for withdrawal‡  
  X  X   X    
Sanofi Pasteur  
 
Confidential/Proprietary Information 
                
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 19 of 90
   
    
 
 
  
    Visit/Contact Visit 1  Telephone 
Call  
(TC) 1 Visit 2  TC2  Visit 3*  TC3  TC4  Visit 4†  TC5 Visit 5  TC6 
Follow -up 
contact 
Contact IRT system for dose allocation 
for all vaccines    X  X   X    
Vaccination with MenACYW conjugate vaccine or MENVEO
® X  X  X   X    
Vaccination with routine pediatric 
vaccines § X  X  X   X    
Immediate surveillance (30 minutes)  X  X  X   X    
Diary card (DC) provided  DC1   DC2   DC3    DC4     
Telephone call   X**  X**  X** X††  X**  X‡‡ 
Diary card reviewed and collected    DC1   DC2    DC3   DC4   
Recording of solicited injection site and systemic reactions§§  X  X  X   X    
Recording of unsolicited AEs   Recorded from D0 to D30 after each vaccination visit  
Reporting of SAEs (including AESIs) and MAAEs 
***  To be reported throughout the study period  
Collection of reportable concomitant medications  X  X  X   X  X  
Memory aid (MA) provided           MA†††   
Trial termination record (termination of active portion of the trial)           X  
* At Visit 3, subjects must be at least 24 weeks of age (the minimum age for the last dose of hepatitis B vaccine) and no more than 32 weeks of age (the maximum age for the last dose of rotavirus 
vaccine). 
† At Visit 4, subjects must be 12 months of age, (from the day subjects turn 12 months  of age  until the day before turning 13 months of age). 
‡ Physical examination should be performed on the basis of relevant medical history at the time of the visit according to the Investigator’s clinical judgment. Temperature needs to be measured before 
each vaccination and recorded in the source documents.  
Sanofi Pasteur  
 
Confidential/Proprietary Information 
                
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 20 of 90
   
    
 
 
  
    § Routine pediatric vaccines at Visit  1: Pentacel®, PREVNAR  13®, RotaTeq®, ENGERIX -B®; at Visit 2: Pentacel®, PREVNAR  13®, and RotaTeq®; at Visit 3: Pentacel®, PREVNAR  13®, RotaTeq®, and 
ENGERIX-B®; at Visit 4: PREVNAR  13®, M-M-R® II, and VARIVAX®. 
** This call is made 8  days after the respective vaccinations. If D08 falls on a weekend or holiday, the telephone call may be made on the following business day. During this telephone call, the staff will 
find out whether the subject experienced any SAE  (including AESIs) and / or MAAE not yet reported, and will remind the subject’s parent / guardian to continue using the diary card, to bring the 
diary card to the study center at the next visit, and confirm the date and time of the next visit.  
†† Staff will contact the subjects’ parent/ guardian by telephone within 14 days before Visit 4 (any time between 14 days and 1 day before Visit 4)  to remind them about the forthcoming study visit. If the 
subject ’s participation in the study  is discontinued, the information recorded on the diary card will be reviewed at this time and the  subject’s parent / guardian will be asked to mail the diary car d 
to the site.  
‡‡ Staff will contact the subject’s parent/ guardian by telephone at 6 months (+  30 days) after the last vaccination visit to identify the occurrence of any SAEs (including any AESIs) and MAAEs not yet 
reported. The final telephone call will  continue until contact is made or 28 days have passed at which time the subject will be considered lost to follow -up. 
§§ Solicited injection site and systemic reactions will be recorded from D0 through D07 after each vaccination visit.  
*** AESIs will be collected throughout the trial as SAEs to ensure that the events are communicated to the Sponsor in an expedited manner and followed up until the end of the follow -up period or 
resolution, as per the assigned causality.  
††† The memory aid is  used only for the recording of SAEs (including AESIs) and MAAEs from Visit 5 to the 6- month follow -up phone call (TC6).  
Sanofi Pasteur  
 
Confidential/Proprietary Information 
                
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 21 of 90
   
    
 
 
  
    List of Abbreviations  
µg micrograms  
ACIP  Advisory Comm ittee on Immunization Practices  
AE adverse even t 
AESI  adverse event of special interest  
AIDS  acquired immune deficiency syndrome 
AR adverse reaction  
CDM  Clinical Data Management  
CI confidence interval 
CQA  Clinical Quality Assessment  
CRA  Clinical Research Associate  
CRB  (electronic) case report book  [all the case report form s for a subject]  
CRF  (electronic) case report form  
CTA  clinical trial agreement  
CTL  Clinical Team Leader  
D Day 
DC diary card  
DTAP  diphtheria tetanus acellular pertussis  
EDC  electronic data capture  
FAS full analysis set  
FDA  Food and Drug Administration 
FHA  filamentous hemagglutinin  
FIM fimbriae types 2 and 3  
FVFS  first visit, first subject  
FVLS  first visit, last subject  
GCI Global Clinical Immunology 
GCP  Good Clinical Practice  
GPV Global Pharmacovigilance  
HBsAg  hepatitis B virus surface antigen  
Hib Haemophilus influenzae  type b 
HIV human immunodeficiency virus 
hSBA  serum bactericid al assay using human complement  
IATA  International Air Transport Association  
ICF informed consent form 
ICH International Conference on Harmonisation 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 22 of 90
   
    
 
 
  
    IEC Independent Ethics Committee  
IM intramuscular  
IMD  invasive meningococcal disease  
IME important medical event 
IND investigational new drug (application)  
IOM  Institute of Medicine  
IPV inactivated poliovirus vaccine  
IRB Institutional Review Board  
IRT interactive response technology 
ITP idiopathic thrombocytopenic purpura  
IU infectious units  
LCLS  last contact, last subject  
LLT lowest level term  
MA memory aid 
MAAE  medically -attended adverse event  
mcg microgram  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
mL Milliliter  
MMR  measles, mumps, rubella  
NSAID  non-steroidal anti -inflammatory drug  
PCV  pneumococcal conjugate vaccine  
PFU plaque -forming units  
pg picogram 
ppm parts per million  
PRN  Pertactin  
PRP polyribosylribitol phosphate 
PPAS  per-protocol analysis set  
PS polysaccharide 
PT pertussis toxin  
PV pharmaco vigilance  
RMO  Responsible Medical Officer  
rSBA  serum bactericidal assay using baby rabbit complement  
SAE  serious adverse event  
SafAS  safety analysis set  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 23 of 90
   
    
 
 
  
    SC Subcutaneous  
SCID  severe combined immunodeficiency  
SMT safety management team  
SOC  system organ class  
TCID 50 tissue culture infectious doses 50%  
TMF  trial master file  
UTN  Universal Trial Number  
v/v Volume  per volume 
WHO  World Health Organization 
 
 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 24 of 90
   
    
 
 
  
    1 Introduction 
1.1 Background 
This study (MET41) will evaluate the safety of a 4 -dose series of the quadrivalent Meningococcal 
Polysaccharide (Serogroups A, C, Y, and W) Tetanus T oxoid Conjugate Vaccine (hereafter 
referre d to as MenACYW conjugate vaccine) in children starting immunization at 6 weeks of age. 
The purpose of the MET41 study is to demonstrate that the safety profile of the MenACYW 
conjugate vaccine is similar to that of MENVEO® when administered concomitantly with routine 
pediatric vaccines given to healthy infants and toddlers in the United States (US)  and Puerto Rico. 
Invasive meningococcal disease (IMD) is a serious illness caused by the bacterium N. 
meningitidis , a Gram -negative diplococcus found exclusively in humans. Symptoms may include 
intense headache, fever, nausea, vomiting, photophobia, stiff neck, lethargy, myalgia, and a characteristic petechial rash  (1). At least 12 different meningococcal serogroups have been 
classified based on the immunochemistry of the capsular polysaccharides (PS). Some strains are more likely than others to cause infection (1) (2) (3). Worldwide, most cases of meningococcal disease are caused by serogroups A, B, C, X, Y, and W  (2) (3) (4). Serogroup B is responsible for 
endemic disease and some outbreaks, while serogroup C is responsible for large outbreaks (5). Serogroup A remains the main cause of epidemics in the world and is especially dominant in 
Africa and Asia. Serogroup W has been observed in Africa, as well as the United Kingdom, in residents who participated in the Hajj pilgrimage to the Kingdom of Saudi Arabia  (4) (6) (7) and 
more recently in Chile  (8), Turkey (9) (10), China  (11) (12), Argentina  (13), Brazil  (14) (15), and 
other parts of the world. Serogroup X causes substantial meningococcal disease in parts of Africa, but rarely causes disease in other parts of the world (2) (16). Serogroup Y has not been associated with outbreaks, but the frequency with which it causes sporadic cases has gradually increased in the US and more recently in Canada and Europe  (17) (18) ( 19). The Y serogroup is commonly 
associated with meningococcal pneumonia, particularly in older adults ≥ 65 years of age  (20). 
Outbreaks of serogroup B meningococcal disease have also been reported on college campuses in the US during the last five -year period: a prolonged outbreak of serogroup B on a university 
campus in Ohio from 2008 – 2010 and 2 universities in New Jersey and California in  2013 (21) 
(22). 
The epidemiology of N. meningitidis  can be described as complex, unpredictable, geographically 
variable, and changing over time. Meningococcal disease occurs worldwide in both endemic and 
epidemic forms with seasonal vari ation. In Europe, the incidence rate of IMD has remained stable 
over the last 5 to 10 years, with the highest peak occurring in the population less than 4 years of age and a smaller peak in the 15 to 19 year old group. The highest incidence rate in Europe is 
caused by serogroup B, followed by C  (23). The highest proportion of meningococcal cases was 
due to serogroup B in the population under 5 years of age. The highest proportion of serogroup C 
cases was observed in the population 25 to 44 years of age while the proportion of serogroup Y cases was highest in the population aged 65 years and above. 
Surveillance data from England and Wales showed an increase in endemic meningococcal 
serogroup W disease across all age groups, accounting for 15% of all IMD cases in 2013 - 2014 compared with an average of 1% to 2% of all IMD cases in earlier years (24). A gra dual increase 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 25 of 90
   
    
 
 
  
    in serogroup Y IMD has also been recently reported in England and Wales between 2007-2009 
(25) and in Swe den during 2005 – 2012 (26) (27). Nearly 50% of all IMD  in Sweden was caused 
by serogroup Y in 2012 (26). Similarly, an increase in the proportion of IMD caused by serogroup 
Y has been observed in other Nordic countries, accounting for 31% in Norway in 2009 - 2010 (28) and 38% in Finland in 2010 ( 29). 
In the US, the incidence rate of IMD was 0.14 per 100,000 in all ages; 0.83 per 100,000 in infants less than 1 year; 0.62 per 100,000 in toddlers 1 year of age; 0.27 per 100,000 in children 2 to 4 years of age; and 0.02 per 100,000 in children 5 to 17 years of age in 2013. The age specific incidence rate per 100,000 was 0.08 in adults 50 to 64 years of age, 0.03 in adults 65 to 74 years of age, 0.14 in adults 75 to 84 years of age, and 0.43 in adults 85 years of age and older in 2013 (30). Serogroups B, C, and Y are the major causes of meningococcal disease in the U S, each 
being responsible for approximately one- third of the overall cases. The proportion of cases caused 
by each serogroup varies by age group. Serogroups C, W, or Y, which are included in vaccines available in the U S, cause 73% of all cases of meningococcal disease among persons 11 years of 
age or older  (31). Approximately 60% of disease among children aged 0 through 59 months is 
caused by serogroup B, for which no conjugate vaccine is licensed or available in the US. More than 50% of meningococcal disease in children 0 to 6 months of age is caused by serogroup B; serogroup Y is also more prevalent in this age group (20).  
The goal for MenACYW conjugate vaccine is to provide broad protection against IMD caused by serogroups A, C, Y, and W in all age groups including children as young as 6 weeks of age, adolescents, and adults, including those 56 years of age and older. 
1.2 Background of the Investigational Product  
1.2.1 Clinical  
The MenACYW conjugate vaccine formulation was finalized based on data provided by 2 studies: MET28, a Phase I study in infants, toddlers, and adults 18 to < 40 years of age; and 
MET32, a Phase I/II study in toddlers. 
The formulation has been evaluated in over 2000 subjects (infants, toddlers, adolescents, and 
adults > 56 years of age) in completed studies MET39, MET44, MET50, MET54 and MET56. MenACYW conjugate vaccine is also being evaluated in ongoing global Phase III studies: 
MET51 and MET57 in toddlers (12 to 23 months of age); MET35 in children (2 to 9 years of age); MET43 (15 to 55 years of age); and MET49 in older adults (≥ 56 years of age). 
MenACYW conjugate vaccine was found to be well tolerated and no unanticipated or new significant safety concerns have been identified in the clinical trials completed to date . The 
relevant Phase II studies are discussed below.  
1.2.1.1 Study MET39 (Phase II)  
MET39 w as a Phase II, randomized, open -label, multi-center study conducted in the US for which 
580 healthy subjects from 2 to 15 months of age were enrolled. This study evaluated the optimal vaccination schedule in the infant/toddler population. Subjects in Group 1 through Group 4 received 1, 2, or 3 primary doses plus an additional dose of the MenACYW conjugate 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 26 of 90
   
    
 
 
  
    vaccine in the second year of life, concomitantly with routine pediatric vaccines at several 
different vaccination schedules. Subjects in Group 5 received 1 dose of the MenACYW conjugate 
vaccine concomitantly with routine pediatric vaccines. The routine pediatric vaccines given concomitantly with MenACYW conjugate vaccine at various schedules included PREVNAR
® 
(pneumococcal conjugate vaccine) or PREVNAR 13® (pneum ococcal 13 -valent conjugate 
vaccine [PCV13]) , Pentacel® (diphtheria, tetanus, pertussis [acellular, component] -poliovirus 
[inactivated]//Haemophilus influenzae type b [ dTaP-IPV//Hib]), ROTARIX® (monovalent 
rotavirus  vaccine [RV1]) or RotaTeq® (pentavalent rotavirus vaccine[RV5]) , hepatitis B vaccine, 
M-M-R® II vaccine (measles, mumps, and rubella vaccine [MMR]) , and VARIVAX® (varicella 
vaccine) . 
Immunogenicity  
After the primary series consisting of 1, 2, or 3 doses of MenACYW conjugate vaccine, protective serum bactericidal assay using human complement (hSBA) threshold titers of ≥ 1:8 were attained by > 88% of subjects for serogroup C and by 62% to 74% for serogroup A. For serogroups Y and W, ≥ 90% achieved the threshold titer after 3 doses, 75% to 84% after 2 doses, but only 25% after a single dose a dministered at 6  months of age. 
After an additional dose of MenACYW conjugate vaccine in the second year of life (12 or 
15 months of age), between 91% and 100% of the subjects achieved the protective threshold regardless of the number of doses they received in the first year of life. 
Safety  
MenACYW conjugate vaccine was well tolerated in infants and toddlers regardless of the 
immunization schedule and the number of doses administered. Safety results were comparable to those seen in control group subjects regardless of the immunization schedule and the number of doses administered. The safety  profile of the licensed vaccines given concomitantly with 
MenACYW conjugate vaccine was similar to that of the licensed vaccines given concomitantly without MenACYW conjugate vaccine. 
No deaths occurred within 30 days. There were 2 subjects in Group 4 who died during the study, 
1 as a result of hypoxic ischemic encephalopathy which started 96 days after the 6-month vaccination and 1 as a result of non- accidental head trauma 36 days after the 12 -month 
vaccination. These events were considered by the Investi gator as unrelated to study vaccine. 
There were 2 other subjects who discontinued the study due to a serious adverse event (SAE) and the receipt of intravenous immunoglobulin treatment: 1 subject in Group 2 with Kawasaki disease, 106  days after the 6 -month vaccination; and 1 subject in Group 3 with middle lobe 
pneumonia and Kawasaki disease, 50 and 52 days, respectively, after the 4 -month vaccinations. 
One other subject in Group 4 was discontinued due to a non- serious adverse event (AE) (viral 
rash 1  day af ter the 6 -month vaccinations). None of these AEs leading to discontinuation were 
considered by the Investigator as related to the vaccine. There were no vaccine- related SAEs 
during this study. 
1.2.1.2 Study MET54 (Phase II)  
MET54 was a Phase II, randomized, open- label, active-controlled, multi- center study conducted 
in Europe (Finland). This study evaluated the immunogenicity and safety profile of a single dose 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 27 of 90
   
    
 
 
  
    of MenACYW conjugate vaccine when given alone in healthy, meningococcal- vaccine naïve 
toddlers compared to that of the licensed vaccine Nimenrix®. A total of 188 meningococcal 
vaccine naïve subjects aged 12 to 23 months on the day of enrollment were randomized to 1 of 
2 groups. Group 1 received a single dose of MenACYW conjugate vaccine and Group 2 received a single dose of Nimenrix
®. 
Immunogenicity  
Antibody responses to the antigens (serogroups A, C, Y, and W) were evaluated by serum bactericidal assay using baby rabbit complement (rSBA) and human complement (hSBA). MenACYW conjugate vaccine immune responses evaluated by rSBA and hSBA were generally comparable to Nimenrix
® immune responses w ith some variation by serogroup. 
rSBA 
Most subjects had rSBA titers ≥ 1:128 at D30. The percentages after MenACYW conjugate 
vaccine were similar (100.0% [91/91] for serogroups A, Y, and W) or numerically higher (100.0% [91/91] for serogroup C) compared to Nimenrix
® (100.0% [86/86] for serogroups A, Y, 
and W and 94.2% [81/86] for serogroup C). At D30, most subjects in both groups demonstrated an rSBA vaccine seroresponse as defined in the SAP and as defined in the protocol. The percentage of subjects with any rSBA vaccine seroresponse by either definition for serogroup A was numerically lower after MenACYW conjugate vaccine (91.2% [83/91]) than Nimenrix
® 
(98.8% [85/86]) and the percentages of subjects with any rSBA va ccine seroresponse by either 
definition were similar or comparable between the 2 groups for serogroups C, Y, and W (all > 96%). 
hSBA 
Most subjects in both groups had hSBA titers ≥ 1:8 at D30: the percentages after MenACYW 
conjugate vaccine for serogroups A, Y, and W (ranging from 97.8% [89/91] to 98.9% [90/91]) 
were comparable to those after Nimenrix
® (ranging from 91.9% [79/86] to 100.0% [86/86]). The 
percentage of subjects with hSBA titers ≥ 1:8 for serogroup C was higher after MenACYW conjugate vaccine ( 100.0% [91/91]) than after Nimenrix
® (89.5% [77/86]). At D30, most subjects 
in both groups demonstrated an hSBA vaccine seroresponse. The percentage of subjects with an hSBA vaccine seroresponse for serogroups A, Y, and W was comparable in both groups (ranging from 96.7% [87/90] to 98.9% [90/91] after MenACYW conjugate vaccine and from 91.9% [79/86] to 98.8% [85/86] after Nimenrix
®). The percentage of subjects with an hSBA vaccine 
seroresponse for serogroup C was higher after MenACYW conjugate vaccine (100.0% [91/91]) than after Nimenrix
® (86.0% [74/86]). 
Safety  
Overall, vaccination with MenACYW conjugate vaccine among toddlers aged 12 to 23 months was found to be safe with no safety concerns identified. The MenACYW conjugate vaccine was well tolerated with no immediate AEs or adverse reactions (ARs), no discontinuations due to an 
SAE or other AE, and no related SAEs. 
The safety profile of MenACYW conjugate vaccine was comparable to that of the licensed 
vaccine Nimenrix
®. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 28 of 90
   
    
 
 
  
    No new clinically important safety findings were identified with administration of the 
MenACYW conjugate vaccine.  The MenACYW conjugate vaccine was well tolerated and 
immunogenic. Single dose of the MenACYW conjugate vaccine demonstrated excellent potential 
to be an alternative vaccine option for toddlers, receiving meningococcal vaccination for the first 
time.  
1.3 Potential Benefits and Risks  
1.3.1 Potential Benefits to Subjects  
MenACYW conjugate vaccine is an investigational vaccine that is undergoing active clinical investigation. There may be no dir ect benefit from receiving the MenACYW conjugate vaccine. 
However, based on the data generated from previous studies, the immunogenicity profile of the MenACYW conjugate vaccine in different age groups shows that the majority of subjects developed seroprot ective levels of antibodies after vaccination. The safety evaluation indicates 
that the vaccine is well -tolerated, and no safety issues have been detected to date. In all, the data 
support further evaluation of the MenACYW conjugate vaccine in humans. 
Subjects who receive MENVEO
® will likely be protected against meningococcal disease caused  
by N. meningitidis serogroups A, C, Y, and W. As with any vaccine, MenACYW conjugate vaccine and MENVEO
® may not protect 100% of 
individuals against the diseases they are designed to prevent. 
1.3.2 Potential Risks to Subjects  
Like other vaccines, MenACYW conjugate vaccine or MENVEO® may cause injection site 
reactions such as pain, swelling, and erythema, or certain systemic events such as fever, 
irritability, drowsiness, loss  of appetite, abnormal crying, and vomiting when administered to 
infants / toddlers . There may be a rare possibility of an allergic reaction, which could be severe. 
There may also be a risk of febrile convulsion in some children who experience high fever. There may be other risks for MenACYW conjugate vaccine or MENVEO
® that are not yet known. 
In a previous study with MenACYW conjugate vaccine (MET32), 1 SAE of reactive arthritis reported in a toddler was considered by the Investigator to be related to the investigational vaccine. The subject developed right knee inflammation the day after receiving MenACYW conjugate vaccine, given by IM injection in the right deltoid. The subject recovered after treatment with ibuprofen and antibiotics. Results of the reactive arthritis investigations performed as part of the workup were not indicative of any specific diagnosis. A point of further consideration was the monoarticular nature of the inflammation in this subject; reactive arthritis would typically be present cli nically in a polyarticular fashion. Importantly, no similar cases have 
been reported following the administration of MenACYW conjugate vaccine in any other completed studies. 
Guillain -Barré syndrome has been reported mostly in persons aged 11 to 19 years w ho had 
symptom onset within 6 weeks of administration of a US licensed meningococcal conjugate 
vaccine (32). A retrospective cohort study carried out in the US using healthcare claims data 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 29 of 90
   
    
 
 
  
    found no evidence of increased Guillain -Barré syndrome risk associated with the use of that 
vaccine. The study was able to exclude all but relatively small incremental risks  (33).  
A review by the Institute of Medicine (IOM) found inadequate evidence to accept or reject a 
causal relationship bet ween tetanus toxoid containing vaccines and Guillain -Barré syndrome  (34). 
The IOM found evidence for a causal relation between tetanus toxoid-containing vaccines and brachial neuritis  (35). Arthus reactions are rarely reported after vacc ination and can occur after 
tetanus toxoid -containing vaccines (36). 
No occurrences of Guillain -Barré syndrome, brachial neuritis, or Arthus reaction have been 
reported with the use of MenACYW conjugate vaccine in the completed clinical trials.  
The potential r isks listed here are not exhaustive. Refer to the Investigator’s Brochure of the 
investigational vaccine and to the package insert for MENVEO
® (37) a s well as the concomitant 
vaccines for additional information regarding potential risks. 
1.4 Rationale  for the Study  
The MenACYW conjugate vaccine is designed for the immunization of individuals of all ages (infants 6  weeks of age and older through and including older adults > 56 years of age) against 
IMD. The purpose of the vaccine is to provide broad coverage against circulating meningococcal strains from serogroups A, C, Y, and W. Compared to a previous Sanofi Pasteur meningococcal conjugate vaccine, Menactra
®, the MenACYW conjugate vaccine is prepared using tetanus toxoid 
as the carrier protein. Conjugation of PS antigens to a protein carrier can induce T  cell-dependent 
immune responses, which are anticipated to give rise to higher antibody titers, longer duration of 
the immune response, and enhanced immunologic memory that allows for a booster response. The program targets licensure of the MenACYW conjugate vaccine in many countries in North America, Europe, Latin America, Africa, the Middle East, and Asia Pacific.  
The MenACYW conjugate vaccine is designed to cover broader age groups than those covered by Menomune
® -A/C/Y/W -135 and Menactra®. Menactra® has been very successful since its 
licensure in 2005; however, it is not licensed in Europe and is not indicated in persons 8 months of age or younger or 56 years of age and older. While Menomune
® -A/C/Y/W -135 and Menactra® 
are currently licensed in different parts of the world, the MenACYW conjugate vaccine is being developed by Sanofi Pasteur to ultimately replace Menomune
® -A/C/Y/W -135 and Menactra® in 
the global market as a quadrivalent meningococcal conjugate vaccine indicated in infants/toddlers, children, adolescents, adults, and older adults > 56 years of age.  
Meningococc al PS vaccines have two important limita tions: a) the antibody response is age-
dependent, with infants giving the poorest response; and b) PSs alone are T -cell independent 
immunogens, and therefore no anamnestic response is seen. The immunogenicity of PS vaccines in infants and children has been shown to be improved by conjugating the PSs to protein carriers. 
Among the key advantages expected of the tetanus carrier is improved immunogenicity in infants and older adults. Pre- clinical studies using a mouse model and investigating different carriers, 
showed significant levels o f PS-specific total immunoglobulin G (IgG) and bactericidal responses 
in response to the formulations with tetanus toxoid as a carrier. Early Phase I/II trials including 
those with the final formulation (MET39 and MET44) showed the potential of the candidate vaccine as a very good immunogen in all age groups, including young infants and older adults. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 30 of 90
   
    
 
 
  
    The MenACYW  conjugate vaccine was found to be immunogenic and well tolerated; it did not 
raise any safety concerns  in the above or subsequent trials using the final formulation or in the 
earlier trials.  
MenACYW conjugate vaccine is being developed for the US infant/toddler population as a 4-dose 
(2, 4, 6, 12 to 18 months of age) and 2-dose se ries. Th ree Phase III studies (including MET41) 
will generate data to primarily support the licensing of the MenACYW conjugate vaccine in the US with an i nfant/toddler indication from 6 weeks of age. The purpose of the MET41 study is to 
describe the safety  profile of the MenACYW conjugate vaccine and the comparator MENVEO
® 
when administered concomitantly with routine pediatric vaccines given to healthy infants and toddlers in the US.  MET41 study will generate data which will significantly contribute towards 
the overall safety database of the MenACYW conjugate vaccine in  the US  and in general. 
2 Study Objective 
To describe the safety profile of MenACYW conjugate vaccine and MENVEO® when 
administered concomitantly with routine pediatric vaccines in healthy infants and toddlers.  
The endpoints for the study  objective are presented in  Section 9.1.1. 
3 Investigators and Study Organization 
This study will be conducted in approximately 65  centers in the US. T he Principal  Investigators 
and any sub- investigators at the individual sites will be  coordinated by 1 Coordinating 
Investigator. Details of the study centers, the Investigators at each center, and the Coordinating 
Investigator are provided  in the “List of Investigators and Centers Involved in the Trial ” 
document. 
An internal safety management team (SMT) will review the data being generated from all the 
ongoing studies with MenACYW conjugate vaccine at regular intervals for any new safety signals 
or safety concerns. 
The Sponsor’s Responsible Medical Officer (the RMO, the person authorized to sign this protocol 
and any amendments on behalf of the Sponsor) is  MD, PhD, Clinical Team Leader  
(CTL) . 
4 Independent Ethics Committee / Institutional Review Board 
Before the investigational product can be shipped to the investigational site and before the 
inclusion of the first subject, this protocol, the informed consent form (ICF), subject recruitment procedures, and any other written information to be provided to subjects must be approved by, and / or receive favorable opinion from, the appropriate Independent Ethics Committee (IEC) or 
Institutional Review Board (IRB).  
In accordance with Good Clinical Practice (GCP) and local regulations, each Investigator and  / or 
the Sponsor are responsible for obtaining this approval and / or favorable opinion before the start 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 31 of 90

   
    
 
 
  
    of the study. If the protocol is subsequently amended, approval must be re-obtained for each 
substantial amendment. Copies of these approvals, along with information on the type, version 
number, and date of document, and the date of approval, must be forwarded by the Investigator to the Sponsor together with the composition of the IEC / IRB (the names and qualifications of the 
members attending and voting at the meetings). 
The Investigator and Sponsor will su bmit written summaries of the status of the study to the IEC  / 
IRB annually, or more frequently if requested. All SAEs occurring during the study that are 
related to the product administered  will be reported by the Investigator to the IEC  / IRB, 
according to the IEC  / IRB policy. 
5 Investigational Plan 
5.1 Description of the Overall Study  Design and Plan  
5.1.1 Study  Design  
This study is a Phase III, modified double-blind, randomized, parallel-group, active-controlled, 
multi-center study to describe the safety of MenACYW conjugate vaccine when administered concomitantly with routine pediatric vaccines given to healthy infants and toddlers in the US. 
Approximately 3080 healthy infants aged ≥ 42 to ≤ 89 days will be randomized in a 3:1 ratio to 
the following 2 groups: 
• Grou p 1: MenACYW conjugate vaccine + routine pediatric vaccines ( N=2310) 
• Group 2:  MENVEO
®+ routine pediatric vaccines  (N=770) 
All subjects will receive a dose of either MenACYW conjugate vaccine or MENVEO® with the 
following routine pediatric vaccines: Pentacel® (DTaP -IPV//Hib) at 2, 4, and 6 months of age ; 
PREVNAR 13® (pneumococcal 13-valent conjugate vaccine; PCV13) at 2, 4, 6, and 12 months of 
age; RotaTeq® (rotavirus vaccine ) at 2, 4, and 6 months of a ge; ENGERIX-B® (hepatitis B 
vaccine) at 2 and 6 months of agea; and M-M-R® II (measles, mumps, and rubella vaccine) and 
VARIVAX® (varicella vaccine) at 12 months of age . All subjects will complete the last study visit 
at 13 to 14 months of age. For all subjects, the 4th dose of Pentacel® should be administered  by 
site personnel  at 15 to 18 months of age as per standard practice.  The 4th dose of Pentacel® will be 
provided by the Sponsor for completion of the DTaP series with vaccine from the same 
manufacturer, to ensure compliance with the Advisory Committee on Immunization Practices 
(ACIP ) recommendation. 
                                                 
a  First dose of hepatitis B vaccine must be given at least 28 days prior to study enrollment.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 32 of 90
   
    
 
 
  
    Study vaccines will be administered as part of the study on the following schedules: 
Group 1:  MenACYW conjugate vaccine and routine pediatric vaccines at 2, 4, 6, and 
12 months of age 
Group 2:  MENVEO® and routine pediatric vaccines at 2, 4, 6, and 12 months of age 
Safety data will be collected as follows: Immediate unsolicited systemic AEs will be collected 
within 30 minutes after each vaccination. Solicited AE information will be collected from D0 to D07 after each vaccination ; unsolicited AE information will be collected from D0 after each 
vaccination to the next study visit; SAE (including adverse events of special interest [ AESIs ]) and 
medically -attended adverse event (MAAE)  information  will be collected throughout the study 
from Visit 1 until the end of the 6-month follow-up period after the last vaccination. 
5.1.2 Justification of the Study  Design  
The MET41 study is part of an  ongoing development program that focuses on demonstrating that 
the safety profile of the MenACYW conjugate vaccine is acceptable and not different from that of licensed quadrivalent meningococcal conjugate vaccines, and that the immunogenicity of the 
MenACYW conjugate vaccine is non -inferior to lice nsed comparators in direct comparison trials. 
MET41  is a pivotal Phase III safety study in which the vaccine can didate will be evaluated in 
infants/toddlers receiving concomitantly licensed routine pediatric vaccines in the US . Thi s study 
is designed to describe the safety profile  following a 4 -dose series of the MenACYW conjugate 
vaccine or the licensed comparator MENVEO
® in this population. Enrol lment in the study will 
start at 6  to 8 weeks of age. 
The concomitant administration of standard of care pediatric vac cines together with 5 different 
administration schedules of the MenACYW conjugate vaccine has been assessed in infants/toddlers 2 to 15 months of age in the US in the MET39 study. The subjects received during, or prior to the study, a number of licensed recommended vaccines at 2, 4, and 6 months of age: Pentacel
®, either Prevnar® or Prevnar 13®, RotaTeq® or ROTARIX®, and ENGERIX-B® or 
RECOMBIVAX HB®. All subjects received M-M-R® II and VARIVAX® at 12 months of age . A 
total of 457 subjects completed the study. The immunogenicity and safety profiles of selected 
licensed pediatric vaccines (Pentacel®, Prevnar® or Prevnar 13®, M-M-R® II, and VARIVAX®) 
were assessed when administered either concomitantly with or without MenACYW conjugate 
vaccine. There was no evidence of interference with the pediatric routine vaccines administered concomitantly with MenACYW co njugate vaccine and the vaccine was safe and well tolerated  
regar dless of the number of doses administered during the firs t year of life . 
In the US, meningococcal vaccination is not routinely recommended for children ≤ 10 years of age, however the vaccination is recommended for individuals at increased risk of disease. ACIP recommends routine administration of quadrivalent meningococcal conjugate vaccine s (MCV4) 
for all persons aged 11 through 18 years. A single dose of vaccine should be administered at age 11 or 12 years, and a booster dose should be administered at age 16 years. In infants at increased 
risk of disease , the ACIP recommends starting vaccination at 8  weeks of age using a 4 -dose 
series that includes doses at 2 ,4, 6 and 12 months of age. Sinc e MENVEO
® is the only 
quadrivalent meningococcal conjugate vaccine licensed for use in infants as young as 2 months of age in the US, t he selection of MENVEO
® as a comparator was considered most appropriate and 
aligned with the MET41 study design. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 33 of 90
   
    
 
 
  
    Given that the meningococcal vaccines used in this study have different appearances  and 
preparation methods, the study has a modified double blind design, and thus , with the exception 
of the personnel administering the vaccine, everyone involved in study (partic ipants, care 
provider, investigator, safety outcomes assessor , Sponsor ) is blinded to avoid any bias.  
5.1.3 Study  Plan 
Vaccination 
All subjects will receive a dose of either MenACYW conjugate vaccine or MENVEO® with 
routine pediatric vaccines at 2, 4, 6, and 12 months of age. All subjects will receive the routine 
pediatric vaccines at the approved ACIP recommended schedules: Pentacel® at 2, 4, and 6 months 
of agea; PREVNAR 13® at 2, 4, 6, and 12 months of age ; RotaTeq® at 2, 4, and 6 months of age ; 
ENGERIX-B® at 2 and 6 months of ageb; and M-M-R® II and VARIVAX® at 12 months of age. 
Study vaccines will be administered according to the following schedules: 
Group 1:  MenACYW conjugate vaccine and routine pediatric vaccines will be administered at 2, 
4, 6, and 12 months of age. Group 2:  MENVEO
® vaccine and routine pediatric vaccines will be administered at 2, 4, 6, and 
12 months of age. 
Blood sampling 
No blood samples will be collected  as this is a safety study.  
Collection of safety data  
• All subjects will be followed for safety from Visit 1 to 6 months after the last vaccinations at 
12 months of age. 
• All subjects will be observed for 30 minutes after each vaccination, a nd any unsolicited 
systemic AEs occurring during that time will be recorded as immediate unsolicited systemic 
AEs in the case report book ( CRB). (See  Section 9.1.1.3.1)  
• The subject’s parent / guardian will record information in a diary card about solicited 
reactions from D0 to D07 after each vaccination and unsolicited AEs from D0 after each 
vaccination to the next study visit. 
• SAEs (including AESIs) and MAAEs will be recorded throughout the study. The subject’s 
parent / guardian will record information in a diary card about SAEs and MAAEs from Visit 1 
to Visit 2, from Visit 2 to Visit 3, from Visit 3 to Visit 4,  and from Visit 4 to Visit 5 . SAEs 
                                                 
a  All subjects will complete the last study visit at 13 to 14 months of age. For all subjects, the 4th dose of Pentacel® 
should be  administered  by site personnel at 15 to 18 months of age  as per standard practice. The 4th dose of 
Pentacel® will be provided by the Sponsor for completion of the DTaP series with vaccine from the same 
manufacturer, as per ACIP recommendation.  
b  First dose of hepatitis B vaccine must be given at least 28 days prior to study enrollment.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 34 of 90
   
    
 
 
  
    and MAAEs will also be recorded in a memory aid from D31 after the last  vaccination visit 
until the 6 -month follow up phone call. 
• The subject’s parent/ guardian will be asked to notify the site immediately about any potential 
SAEs at any time during the trial.  
• Site s taff will contact the subjects’ parent/ guardian by telephone 8 days (+2 days) after each 
vaccination visit to identify the occurrence of any SAEs (including AESIs)  and/or MAAEs not 
yet reported and to remind them to complete t he diary card after each vaccination visit and to 
bring it back at the subsequent visit. 
• The completed diary cards will each be collected and reviewed with the subject’s parent/ 
guardian at the subsequent visit. 
• Site staff will contact the subjects’ parent / guardian by telephone within 14 days before Visit 4 
to remind them about the forthcoming study visit. If the subject ’s participation  in the study is 
discontinued, the information recorded on the diary card will be reviewed at this time and the 
subject’s parent / guardian will be asked to mail the diary card to the site.  
• Site staff will contact the subjects’ parent/ guardian by telephone at 6  months (+30 days) after 
the last vaccination visit to review the memory aid and identify the occurrence of any MAAE s, as well as SAEs (including AESIs) that have not been reported. 
Table 5.1: Vaccination schedule  
Visit/Contact  Visit 1  Visit 2  Visit 3  Visit 4  
Age of Subject  2 months  4 months  6 months  12 months  
Group 1  MenACYW  
DTaP -IPV//Hib  
PCV13 
Rotavirus  
Hep B  MenACYW  
DTaP -IPV//Hib  
PCV13 
Rotavirus  MenACYW  
DTaP -IPV//Hib  
PCV13 
Rotavirus  
Hep B  MenACYW  
PCV13 
MMR  
Varicella  
Group 2  MENVEO  
DTaP -IPV//Hib  
PCV13 
Rotavirus  
Hep B  MENVEO  
DTaP -IPV//Hib  
PCV13 
Rotavirus  MENVEO  
DTaP -IPV//Hib  
PCV13 
Rotavirus  
Hep B  MENVEO  
PCV13 
MMR  
Varicella  
DTaP -IPV//Hib: Pentacel®; PCV13: PREVNAR  13®; Rotavirus: RotaTeq®; Hep B: ENGERIX-B®; MMR: M-M-R® II; 
Varicella:  VARIVAX® 
 
5.1.4 Visit Procedures 
Visit 1 ( D0; 2 months of age ): Inclusion, Randomization, and Vaccination 
1) Give the parent / guardian information about the study, obtain written informed consent, and 
give him/her a signed copy. 
2) Check inclusion and exclusion criteria for eligibility. 
3) Collect demographic data.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 35 of 90
   
    
 
 
  
    4) Obtain verbal medical history about the subject , including ongoing medications. 
5) Perform a physical examination, including, but not limited to, examination of the head (ear, 
nose, and throat), neck, heart, lungs, abdomen, and extremities. If a routine examination had been performed within the past week by a qualified health care provider, it does not need to be repeated unless there were changes in health status, in which case it may be limited to the affected area.  
6) Measure temperature. If the temperature is ≥38°C (≥ 100.4°F), postpone vaccination until the condition is resolved.  
7) Contact the interactive response technology (IRT) system for randomization, subject number, 
and vaccine allocation . 
8) Review warnings and precautions to vaccinations. 
9) Administer the following study vaccines. Each vaccine should be administered  in the assigned 
location (see Operating Guidelines) and documented appropriately. 
a) Meningococcal vaccine (MenACYW conjugate vaccine and MENVEO
®): inject IM 
into the anterolatera l area of the thigh, preferably the right thigh. 
b) ENGERIX-B®: inject IM into the anterolateral area of the thigh , preferably the right 
thigh. 
c) Pentacel®: inject IM into the anterolateral area of the thigh , preferably the left thigh  
(i.e., the opposite leg from that used for meningococcal vaccine administration). 
d) PREVNAR 13®: inject IM into the anterolateral area of the th igh preferably the left 
thigh (i.e., the opposite leg from that used for meningococcal vaccine administration).  
e) RotaT eq
®: administer orally per instructions in the package insert.  
When  multiple vaccines are administered at a single visit, each vaccine should be 
administered at a different anatomic site.  The injection sites should be separated by 
1 inch or more so that any local reactions can be differentiated  (38). Meningococcal 
vaccine and Engerix-B® should be given in the same thigh. Do not administer 
Pentacel® or PREVNAR 13® in the same thigh as the meningococcal vaccine. For 
details see Operating Guidelines.  
Failure to administer vaccines in the designated limb will not constitute a protocol deviation, but should be recorded a s a comment in the CRF. If the initial vaccines are 
administered in the wrong limbs, this should be corrected for subsequent injections. 
10) Observe the subject for 30 minutes and record any AEs in the source document. In the event of a local reaction, indicat e the associated vaccine.  
11) Give the parent / guardian a diary card  (DC1) , a thermometer, and a ruler, and go over the 
instructions for their use.  Instruct the parent / guardian to retain the thermometer and ruler 
throughout the duration of the study. At each subsequent visit, confirm that the parent / guardian has retained the thermometer and ruler, replace only as necessary  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 36 of 90
   
    
 
 
  
    12) Remind the parent / gua rdian to expect a telephone call 8 days after Visit  1 and to bring back 
the diary card when they return for Visit 2 at a specified date and time.  
13) Remind the parent / guardian to notify the site in case of an SAE.  
14) Complete the relevant case report forms (CR Fs) for this visit.   
Telephone Call 1 (8  [+2]  days after Visit 1)  
Note : If day 8 after vaccination falls on a weekend or a holiday, the telephone call may be made 
on the following business day. 
1) Record relevant information concerning the subject’s health status on the telephone contact 
form. If an SAE, including an AESI, has occurred, follow the instructions in Section 10 fo r 
reporting it. 
2) Remind the parent / guardian to do the following: 
• Complete the D0  to D07 pages of the diary card.  
• Complete the remaining pages of the diary card, and bring them to the next visit . 
• Notify the site in case of an SAE . 
Visit 2 (60 [+14] days after Visit 1; 4 months of age ): Collection of Safety Information  and 
Vaccination 
1) Collect and r eview the diary card  (DC1)  with the parent / guardian, including any AEs , 
medications, or therapy t hat occurred since the last visit. If an SAE, including an AESI, has 
occurred, follow the instructions in Section 10 fo r reporting it. 
2) Review warnings and precautions to vaccinations. 
3) Review contraindications to subsequent vaccinations and condition for withdrawal. 
4) Measure temperature prior to vaccination. If the temperature is ≥ 38°C (≥ 100.4°F), postpone 
vaccination until the condition is resolved.  
5) Contact IRT system to receive vaccine assignments. 
6) Administer the  following study vaccines. Each vaccine should be administered in an assigned 
location and documented appropriately. 
a) Meningococcal vaccine (MenACYW conjugate vaccine or MENVEO®): inject IM 
into the  anterolateral area of the  thigh , preferably the right thigh. 
b) Pentacel®: inject IM into the anterolateral area of the  thigh, preferably the left thigh  
(i.e., the opposite leg from that used for meningococcal vaccine administration) . 
c) PREVNAR 13®: inject IM into the anterolateral area of the thigh, preferably the left 
thigh (i .e., the opposite leg from that used for meningococcal vaccine administration). 
d) RotaT eq®: administer orally per instructions in  the package insert.  
When  multiple vaccines are administered at a single visit, each vaccine should be 
administered at a different anatomic site. The injection sites should be separated by 1 inch or more so that any local reactions can be differentiated  (38). Do not administer 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 37 of 90
   
    
 
 
  
    Pentacel® or PREVNAR 13® in the same thigh as the meningococcal vaccine. For 
details see Operatin g Guidelines. 
Failure to administer vaccines in the designated limb will not constitute a protocol 
deviation, but should be recorded as a comment in the CRF.  
7) Observe the subject for 30 minutes and record any AE in the source document. In the event of 
a local reaction, indicate the associated vaccine.  
8) Give the parent / guardian a diary card (DC2). 
9) Remind the parent / guardian to expect a telephone call 8 days after Visit  2 and to bring back 
the diary card when they return for Visit 3 at a specified date and  time . 
10) Remind the parent / guardian to notify the site in case of an SAE. 
11) Complete the relevant CRFs for this visit.  
Telephone Call 2 (8 [+2] days after Visit 2)  
Refer to steps in Telephone Call 1 . 
 
Visit 3 (60 [+14] days after Visit 2; 6 months of age ): Collection of Safety Information and 
Vaccination 
1) Collect and review the diary card (DC2) with the parent / guardian, including any AEs, 
medications, or therapy that occurred since the last visit. If an SAE, including an AESI, has 
occurred, follow the instructions in  Section 10 fo r reporting it. 
2) Review warnings and precautions to vaccinations. 
3) Review contraindications to subsequent vaccinations and conditions for withdrawal. 
4) Measure temperature prior to vaccination. If the temperature is ≥ 38°C (≥ 100.4°F), postpone 
vaccination until the condition is resolved.  
5) Contact IRT  system  to receive vaccine assignments. 
6) Administer the appropriate study vaccine s as described for Visit 1 . 
7) Observe the subject for 30 minutes and record any AE in the source document. In the event of 
a local reaction, indicate the associated vaccine.  
8) Give the parent / guardian a diary card (DC3). 
9) Remind the parent / guardian to expect a telephone call 8  days after Visit  3. 
10) Remind the parent / guardian to expect a telephone call within 14 days before the next visit, Visit 4, and to bring back the diary card when they return for that visit. 
11) Remind the parent / guardian to notify the site in case of an SAE.  
12) Complete the relevant CRFs for this visit.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 38 of 90
   
    
 
 
  
    Telephone Call 3 (8 [+2] days after Visit 3)  
Refer to steps in Telephone Call 1 . 
Telephone Call 4 (within 14 days before Visit 4) 
1) Contact the subjects’ parent/ guardia n by telephone within 14 days before Visit 4 to remind 
them about the forthcoming study visit. 
2) If the subject will not continue in the study:  
a) Review the diary card including any AEs, medications, or therapy that occurred since 
the last visit.  
b) Ask the subj ect’s parent / guardian if the subject has experienced any SAE and / or 
MAAE in the time since vaccination that has not been reported to the study personnel. 
If an SAE, including an AESI, has occurred, follow the instructions in Section 10 for reporting it. 
c) Ask the subject’s parent / guardian to mail the diary card to the site.  
Visit 4 (6 months after Visit 3 [Subject must be 12 months of age]): Collection of Safety 
Information and Vaccination 
1) Collect and review the diary card  (DC3)  with the parent / guardian, including any AEs, 
medications, or therapy that occurred since the last visit. If  an SAE, including an AESI, has 
occurred, follow the instructions in Section 10 fo r reporting it. 
2) Perform a physical examination, including, but not limited to, examination of the head (ear, 
nose, and throat), neck, heart, lungs, abdomen, and extremities. If a routine examination had been performed within the past week by a qualified health care provider, it does not need to be repeated unless there were changes in health status, in which case it may be limited to the affected area.  
3) Measure temperature. If the temperature is ≥ 38°C (≥ 100.4°F ), postpone vaccination until the 
condition is resolved.  
4) Review warnings and precautions to vaccinations. 
5) Review contraindications to subsequent vaccinations and conditions for withdrawal. 
6) Contact IRT system to receive vaccine assignments. 
7) Administer the following study vaccines. Each vaccine should be administered in an assig ned 
location (see Operating Guidelines) and documented appropriately. 
a) Meningococcal vaccine (MenACYW conjugate vaccine or MENVEO
®): inject IM 
into the anterolateral area of the thigh , preferably the right thigh. Do not administer 
any other vaccine with the meningococcal vaccine in the same thigh. 
b) PREVNAR 13®: inject IM into the anterolateral area of the thigh, preferably the left 
thigh (i.e., the opposite leg from that used for meningococcal vaccine administration). 
c) M-M-R® II : inject SC  into the ou ter aspect of the upper arm . 
d) VARIVAX ®: inject SC into the outer aspect of the upper arm. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 39 of 90
   
    
 
 
  
    e) When  multiple vaccines are administered at a single visit, each vaccine should be 
administered at a different anatomic site. The injection sites should be separated by  1 
inch or more so that any local reactions can be differentiated  (38). 
f) Failure to administer vaccines in the designated limb will not constitute a protocol 
deviation, but should be recorded as a comment in the CRF. 
8) Observe the subject for 30 minutes and record a ny AE in the source document. In the event of 
a local reaction, indicate the associated vaccine.  
9) Give the parent / guardian a diary card (DC4) 
10) Remind the parent / guardian to notify the site in case of an SAE. 
11) Complete the relevant CRFs for this visit.  
Telephone Call 5 (8 [+2] days after Visit 4)  
Refer to steps in Telephone Call 1 . 
Visit 5 (30 [+21] days after Visit 4): Collection of Safety Information  
1) Collect and review the diary card (DC4) with the parent / guardian, including any AEs, 
medications, or therapy that occurred since vaccination. If an SAE, including AESI, has 
occurred, follow the instruction in Section 10 fo r reporting it.  
2) Give the parent / guardian a MA to record SAE and MAAEs from Visit 5 until the 6 -month 
follow-up phone call. 
3) Remind the parent / guardian to notify the site in case of an SAE.  
4) Complete the trial termination record . 
Safety Follow-up Telephone Call (180 [+30] days after Visit  4): Collection of SAEs  
(including AESIs) and MAAEs  
1) Ask the parent / guardian if the subject has experienced any SAE  and / or MAAE  since the 
last study visit . If an SAE, including an AESI, has occurred, follow the instructions in 
Section  10 fo r reporting it.  
2) Complete the relevant CRFs for this visit.  
This call must be made by a qualified person.  
A follow-up visit outside the scope of this study protocol can be arranged depending on the information recorded during the phone call. 
Follow- up of subjects with Related AEs or with AEs That Led to Study/Vaccination 
Discontinuation:  
A subject who experiences an AE (whether serious or non-serious) during the study must be 
followed until the condition resolves, becomes stable, or becomes chronic (even after the end of the subject’s participation in the study) if either of the following is true:  
• The AE is considered by the Investigator to be related to the product administered. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 40 of 90
   
    
 
 
  
    • The AE caused  the discontinuation of the subject from the study or from vaccination. 
5.1.5 Planned Study Calendar  
The following dates are approximate. The actual dates may differ as, for example, the study will 
not start until all the appropriate regulatory and ethical appro vals have been obtained. 
Planned study period - FVFS (first visit, first subject) to LCLS (last contact, last subject) : 17 
September  2018 to 05 April 2021 
Planned inclusion period - FVFS to  FVLS (first visit, last subject ): 17 September  2018 to 17 
September  2019 
Planned end of study: 05 April 2021 
Planned date of final clinical study report: 08 October 2021 Telephone call 6 (6-month follow up) of the last subject in either group is considered to be the end 
of the study. 
5.1.6 Early Safety Data Review 
No Early Safety Data Review (i.e., no early safety review[s] of preliminary safety data occurring 
at pre -determined milestones defined in the protocol, with pause in enrollment) is planned for this 
trial as MenACYW conjugate vaccine has been previously adm inistered to infants, toddlers, and 
adults with an acceptable safety profile and no safety concerns have been identified in the clinical trials completed so far. There will be an internal team at the level of the Sponsor (Safety Management Team, [SMT]), wh ich will review the data being generated from all the ongoing 
studies with MenACYW conjugate vaccine at regular intervals for any new safety signals or safety concerns. The SMT is empowered to recommend a pause in both recruitment and/or further 
vaccinatio n while it investigates any potential signal or concern.  
This study may be interrupted at any time if new data about the investigational product become 
available, and/or on advice of the Sponsor, the Independent Ethics Committees (IECs) / Institutional Rev iew Boards (IRBs), or the governing regulatory authorities in the US where the 
trial is taking place.  
If the study is prematurely terminated or suspended, the Sponsor will promptly inform the 
Investigators, the IECs/IRBs, and the regulatory authorities of the reason for termination or suspension. If the trial is prematurely terminated for any reason, the Investigator will promptly inform the subjects’ parents / guardians and should assure appropriate therapy (if needed) and follow-up. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 41 of 90
   
    
 
 
  
    5.2 Enrollment and Retention of Study Population  
5.2.1 Recruitment Procedures 
Each site will be responsible for devising a recruitment plan for enrolling eligible subjects. 
Advertisements and other recruitment aids will be approved by Sanofi Pasteur and the site’s IRB/IEC prior to use by  the clinical site.  
5.2.2 Informed Consent Procedures 
Informed consent is the process by which a subject and / or a parent / guardian voluntarily 
confirms his or her willingness to participate  / allow the child to participate  in a particular study. 
Informed consent must be obtained before any study procedures are performed. The process is 
documented by means of a written, signed, and dated ICF. 
In accordance with GCP, prior to signing and dating the consent form, the parent / guardian must be 
informed by appropri ate study personnel about all aspects of the study that are relevant to making 
the decision to participate, and must have sufficient time and opportunity to ask any questions. 
The actual ICF used at each center may differ, depending on local regulations and IEC  / IRB 
requirements. However, all versions must contain the standard information found in the sample 
ICF provided by the Sponsor. Any change to the content of the ICF must be approved by the Sponsor and the IEC / IRB prior to the form being used. 
If new information becomes available that may be relevant to the parent’s / guardian’s willingness 
to continue participation in the study, this will be communicated to him / her in a timely manner. 
Such information will be provided via a revised ICF or an addendum to the original ICF. 
ICFs  will be provided in duplicate, or a photocopy of the signed consent will be made. The 
original will be kept by the Investigator, and the copy will be kept by the subject ’s parent / 
guardian. Documentation of the consent process should be recorded in the source documents. 
5.2.3 Screening Criteria  
There are no screening criteria other than the inclusion and exclusion criteria.  
5.2.4 Inclusion Criteria  
An individual must fulfill all of the following criteria to be eligible for study  enrollment: 
1) Aged ≥ 42 to ≤ 89 days on the day of the first study visit. 
2) Health y infants as determined by medical history, physical examination, and judgment of the 
Investigator. 
3) Informed consent form has been signed and dated by the parent(s) or guardian (and by an 
independent witness if required by local regulations). 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 42 of 90
   
    
 
 
  
    4) Subject and parent/guardian are able to attend all scheduled visits and to comply with all trial 
procedures. 
5) Infants who received the first dose of hepatitis B vaccine at least 28 days before the fi rst study 
visit.  
5.2.5 Exclusion Criteria  
An individual fulfilling any of the following criteria is to be excluded from study enrollment: 
1) Participation at the time of study enrollment or in the 4 weeks preceding the first trial 
vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.  
2) Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned receipt of any vaccine in the 4 weeks before and / or following any trial vaccination except for influenza vaccination, which may be received at least 2 weeks before or 2 weeks after any study vaccination. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.  
3) Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, PS , or conjugate meningococcal vaccine containing 
serogroups A, C, Y, or W; or meningococcal B serogroup- containing vaccine). 
4) Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis A, measles, mumps, rubella, varicella; and Haemophilus influenzae  type b, Streptococcus pneumoniae , 
and /or rotavirus infection or disease . 
5) Receipt of more than 1 previous dose of hepatitis B vaccine. 
6) Receipt of immune globulins, blood or blood-derived products since birth. 
7) Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti- cancer chemotherap y or radiation therapy; or long-
term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks) since birth.  
8) Family history of congenital or hereditary immunodeficiency until the immune competence of the potential vaccine recipient is demonstrated.  
9) Individuals with blood dyscrasias, leukemia, lymphoma of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems. 
10) Individuals with active tuberculosis 
11) History of any Neisseria meningitidis infection, confirmed either clinically, serologically, or 
microbiologically. 
12) History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, hepatitis A, measles, mumps, rubella, varicella, Haemophilus influenzae  type b, Streptococcus pneumoniae , and /or 
rotavirus infection/disease.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 43 of 90
   
    
 
 
  
    13) At high risk for meningococcal infection during the trial (specifically, but not limited to, 
subjects with persistent complement deficiency, with anatomic or functional asplenia, or 
subjects traveling to countries with high endemic or epidemic disease).  
14) History of intussusception.  
15) History of any neurologic disorders, including seizures and progressive neurologic disorders. 
16) History of Guillain -Barré syndrome. 
17) Known systemic hypersensitivity to any of the vaccine components or to latex, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the 
same substances, including neomycin, gelatin, and yeast
a. 
18) Verbal report of thrombocytopenia contraindicating intramuscular vaccination in the Investigator’s opinion. 
19) Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination in the Investigator’s opinion  
20) Chronic illness (including, but not limited to, cardiac disorders, congenital heart disease, 
chronic lung disease, renal disorders, auto -immune disorders, diabetes, psychomotor diseases, 
and known congenital or genetic diseases) that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion  
21) Any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives. 
22) Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38°C [≥  100.4°F]). A prospective subject should 
not be included in the study until the condition has resolved or the febrile event has subsided. 
23) Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study. 
If the subject has a primary physician who is not the Investigator, the site must contact the 
primary  physician with the parent’s / guardian’s consent  to inform him / her of the subject’s 
participation in the study. In addition, the site should ask this primary physician to verify 
exclusion criteria relating to previous therapies, such as receipt of blood  products or previous 
vaccines.  
5.2.6 Medical History  
Prior to  enrollment, subjects will be assessed for pre-existing conditions and illnesses, both past 
and ongoing. Any such conditions will be documented in the source document. Significant (clinically relevant ) medical history (reported as diagnosis) including conditions /illnesses for 
which the subject is or has been followed by a physician or conditions /illnesses that could resume 
during the course of the study or lead to an SAE or to a repetitive outpatient c are will be collected 
                                                 
a  The components of all study vaccines are listed in Section 6.1.1  and in the  Investigator’s Brochure  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 44 of 90
   
    
 
 
  
    in the CRB. The significant medical history section of the CRB contains a core list of body 
systems and disorders that could be used  to prompt comprehensive reporting, as well as space for 
the reporting of specific conditions and illnesses.  
For each condition, the data collected will be limited to:  
• Diagnosis (this is preferable to reporting signs and symptoms) 
• Presence or absence of the condition at enrollment  
The reporting of signs and symptoms in lieu of a diagnosis is strongly discouraged. 
Dates, medications, and body systems are not to be recorded, and the information collected will not  
be coded. Its purpose is to assist in the later interpretation of safety data collected during the 
study. 
5.2.7 Contraindications for Subsequent Vaccinations  
5.2.7.1 Temporary Contraindications 
Should a subject experience one of the conditions listed below, the Investigator will postpone 
further vaccination until the condition is resolved. Postponement must still be within the timeframe for vaccination indicate d in the Table of Study Procedures . 
• Febrile illness (temperature ≥ 38°C [≥ 100.4°F] ) or moderate or severe acute illness / infection 
on the day of vaccination, according to Investigator judgment. 
• Receipt of any vaccine (other than the study vaccines) in the 4  weeks preceding the first study 
vaccination or planned receipt of any vaccine in the 4 weeks before or following any study vaccination except for influenza vaccination, which may be received at least 2 weeks before or 2 weeks after any study vaccinatio n. This exception includes monovalent pandemic influenza 
vaccines and  multivalent influenza vaccines.  
5.2.7.2 Definitive Contraindications  
Prior to vaccination, check the complete list of contraindications  for each  individual vaccine to be 
administered. For the licensed vaccines refer to the individual current package inserts. For MenACYW conjugate vaccine refer to the Investigator’s Brochure.  
Should a subject experience an anaphylactic or other significant allergic reaction to the previous 
dose of vaccine, the Investigat or will discontinue vaccination.  
Subjects with a definitive contraindication will continue to be followed up for the study -defined 
safety, as applicable.  
The following AEs constitute absolute contraindications to subsequent vaccination with any of the study vaccines. If a subject should experience any of these events during the study, that subject is not to receive any additional study vaccines but will continue to be followed up during the study per the study defined safety as applicable. 
 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 45 of 90
   
    
 
 
  
    Mening ococcal vaccines (MenACYW conjugate vaccine and MENVEO®): 
1) History of an Arthus- like reaction after vaccination with a tetanus toxoid -containing vaccine.  
2) History of Guillain -Barré syndrome within 6 weeks after vaccination with a tetanus toxoid-
containing vaccine  
3) Severe allergic reaction (e.g., anaphylaxis) after a previous dose of vaccine, any component of 
the vaccines, or any other CRM 197, diphtheria toxoid or meningococcal-containing vaccine. 
Pentacel®: DTaP -IPV//Hib vaccine  
4) Severe allergic reaction (e.g., anaphylaxis) after a previous dose of Pentacel®, any ingredient 
of Pentacel®, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, 
inactivated poliovirus vaccine or H. influenzae  type b vaccine.  
5) Encephalopathy within 7 days of a previous pertussis-containing vaccine with no other identifiable cause.  
6) Progressive neurologic disorder including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized.  
PREVNAR  13
®: pneumococcal 13 -valent conjugate vaccine; PCV13 
7) Severe allergic reaction (e.g., anaphylaxis) to any component of PREVNAR 13® or any 
diphtheria toxoid-containing vaccine. 
ENGERIX-B®: hepatitis B vaccine  
8) Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B-containing 
vaccine, or to any component of ENGERIX-B®, including yeast. 
RotaTeq®: rotavirus vaccine  
9) Demonstrated history of hypersensitivity to the rotavirus vaccine or any component of the vaccine. 
10) Episode of intussusception. 
11) History of severe combined immunodeficiency (SCID). 
M-M-R
® II: measles, mumps, and rubella vaccine  
12) Hypersensitivity to any component of the vaccine, including gelatin. 
13) Anaphylactic or anaphylactoid reactions to neomycin  
14) Patients receiving immunosuppressive therapy. This contraindication does not apply to 
patients who are receiving corticosteroids as replacement therapy, e.g., for Addison’s disease.  
15) Individuals with newly diagnosed ( after inclusion in the study ), blood dyscr asias, leukemia, 
lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems.  
16) Newly diagnosed ( after inclusion in the study ) primary and acquired immunodeficiency states, 
including patients who are immunosuppressed in association with acquired immune 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 46 of 90
   
    
 
 
  
    deficiency syndrome (AIDS) or other clinical manifestations of infection with human 
immunodeficiency viruses; cellular immune deficiencies; and hypogammaglobulinemic and 
dysgammaglobulinemic states.  
17) Individuals with family  members newly diagnosed ( after subject’s inclusion in the study) with  
congenital or he reditary immunodeficiency, unless  the immune competence of the potential 
vaccine recipient has been demonstrated. 
VARIVAX®: varicella vaccine  
18) History of severe allergic reaction to any component of the vaccine (including neomycin and 
gelatin) or to a previous dose of varicella vaccine.  
19) Newly diagnosed (after inclusion in the study)  primary or acquired immunodeficiency states, leukemia, lymphoma or other malignant neoplasms affecting the bone marrow or lymphatic system, AIDS, or other clinical manifestations of infection with human immunodeficiency virus (HIV).  
20) Individuals receiving immunosuppressive therapy, including individuals receiving immunosuppre ssive doses of corticosteroids.  
A substantially immunosuppressive steroid dose is considered to be ≥ 2 weeks of daily receipt of 20 mg or 2 mg/kg body weight of prednisone or equivalent. For further information on contraindications to Varivax vaccination in persons receiving immunosuppressive therapies, consult the General Best Practices Guidelines for Immunization  (39), the Recommendations 
of the Advisory Committee on Immunization Practices (ACIP) (40), and the Pinkbook (41).  
21) Active, untreated tuberculosis.  
In the event of a local or national immunization program with a pandemic influenza vaccine, 
subjects who receive pandemic influenza vaccine at any time during the study will not be 
withdrawn from the study. 
5.2.7.3 Warnings and Precautions to Vaccination  
Prior to vaccination, check the warnings and precautions for each  individual vaccine to be 
administered. For the licensed vaccines refer to the individual package inserts. For MenACYW 
conjugate vaccine refer to the Investigat or’s Brochure. 
5.2.8 Conditions for Withdrawal  
Parents / guardians will be informed that they have the right to withdraw their child  from the 
study at any time.  
A subject may be withdrawn from the study: 
• At the discretion of the Investigator or Sponsor due to safety concerns or significant non-
compliance with the protocol (based on the Investigator’s judgment), without the subject’s 
permission  (withdrawal)  
• At the request of the parent / guardian (dropout) 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 47 of 90
   
    
 
 
  
    The reason for a withdrawal or dropout should be clearly documented in the source docum ents 
and on the CRB .  
The Investigator must determine whether voluntary withdrawal is due to safety concerns (in 
which case, the reason for discontinuation will be noted as “Adverse Event”) or for another reason . 
Withdrawn subjects will not be replaced. 
5.2.9 Lost to Follow- up Procedures  
In the case of subjects who fail to return for a follow-up examination, documented reasonable 
effort (i.e., documented telephone calls and certified mail) should be undertaken to locate or recall them, or at least to determine th eir health status while fully respecting their rights. These efforts 
should be documented in the CRB and in the source documents. 
5.2.10 Classification of Subjects Who Discontinue the Study  
For any subject who discontinues the study prior to completion, the most significant reason for 
early termination will be checked in the CRB. Reasons are listed below from the most significant 
to the least significant (refer to the CRF Completion Instructions for additional details and 
examples) : 
Adverse Event  To be used when the subject is permanently terminated from the study because of an AE 
(including an SAE), as defined in Section 9.1.1.1 . 
This category also applies if the subject experiences a definitive contraindication that is an SAE 
or AE.  
Lost to Follow -
up To be used when the subject cannot be found or contacted in spite of efforts to locate him/her before the date of his/her pla nned last visit, as outlined in  Section 5.2.9 . The certified letter was 
sent by the Investigator and returned unsigned, and the parent/guardian did not give any other 
news and did not come to any following visit.  
Protocol 
Deviation  To be used:  
In case of significant non -compliance with the protocol (e.g., deviation of the Inclusion / 
Exclusion criteria, non -compl iance with time windows, vaccination refusal, missed 
injection/treatment, or error in the vaccine/treatment administration).  
If the subject experiences a definitive contraindication that is a protocol deviation.  
The parent/guardian signed the certified letter sent by the Investigator but did not give any other 
news and did not come to any following visit.  
Withdrawal by Parent / Guardian  To be used:  
When the parent/guardian indicated unwillingness to continue in the study  
When the parent/guardian made the decision to discontinue participation in the study  for any 
personal reason other than an SAE/AE (e.g., subject is relocating, inform consent withdrawal, 
etc.) 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 48 of 90
   
    
 
 
  
    5.2.11 Follow- up of Discontinuations  
The site should complete all sch eduled safety follow-ups and contact the parent/guardian of any 
subject who has prematurely terminated the study because of an AE, a protocol deviation, or loss 
of eligibility, including definitive contraindications.  
For subjects where the reason for earl y termination was lost to follow -up or if the subject ’s 
parent/guardian withdrew informed consent and specified that they do not want to be contacted again and it is documented in the source document, the site will not attempt to obtain further safety info rmation. 
If the subject’s status at the end of the study is “Withdrawal by Parent / Guardian”, the site will attempt to contact them for the 6-month follow- up except if they specified that they do not want to 
be contacted again and it is documented in the source document. 
For subjects where the reason for early termination is voluntary withdrawal, the site will attempt 
to contact them for the 6 -month follow-up except if they specified that they do not want to be 
contacted again and it is documented in the source document. 
5.3 Safety Emergency Call  
If, as per the Investigator's judgment, a subject experiences a medical emergency, the Investigator may contact the Sponsor's RMO for advice on study  related medical question or problem. If the 
RMO is not available, th en the Investigator may contact the Call Center— available 2 4 hours a 
day, 7 days a week —that will forward all safety emergency calls to the appropriate primary or 
back -up Sanofi Pasteur contact, as needed. The toll- free contact information for the Call Center is 
provided in the Operating Guidelines. 
This process does not replace the need to report  an SAE. The Investigator is still required to 
follow the protocol-defined process for reporting SAEs to the Global Pharmacovigilance ( GPV) 
Department (Please r efer to  Section 10 ). 
In case of emergency code-breaking, the Investigator is required to follow the code-breaking 
procedures descr ibed in  Section 6.4.  
5.4 Modification of the Study  and Protocol  
Any amendments to this study plan and protocol must be discussed with and approved by the Sponsor. If agreement is reached concerning the need for an amendment, it will be produced in writing by the Sponsor, and the amended version of the protocol will replace the earlier version. All substantial amendments (e.g., those that affect the conduct of the study or the safety of 
subjects) require IEC  / IRB app roval, and must also be forwarded to regulatory authorities. 
An administrative  amendment to a protocol is one that modifies some administrative , logistical, or 
other aspect of the study but does not affect its scientific quality or have an impact on the 
subjects’ safety. The IECs / IRBs  should be notified, but no formal approval will be required. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 49 of 90
   
    
 
 
  
    The Investigator is responsible for ensuring that changes to an approved study, during the period 
for which IEC / IRB approval has already been given, are not initiated without IEC / IRB review 
and approval, except to eliminate apparent immediate hazards to subjects.  
5.5 Interruption of the Study  
The study may be discontinued if new data about the investigational product resulting from this or 
any other studies become available; or for administrative reasons; or on advice of the Sponsor, the 
Investigators, the IECs/ IRBs , or the governing regulatory authorit ies in the country where the 
study is taking place .  
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigators, the IECs/ IRBs , the regulatory authorities, and any contract research organizations 
used in the study of the reason for termination or suspension, as specified by the applicable regulatory requirements. The Investigator shall promptly inform the subjects’ parents / guardians and should assure appropriate subject therapy and/or follow- up. 
There will b e an internal team at the level of the Sponsor (Safety Management Team, [SMT]), 
which will review the data being generated from all the ongoing studies with MenACYW conjugate vaccine at regular intervals for any new safety signals or safety concerns. The SMT is empowered to recommend a pause in both recruitment and / or further vaccination while it investigates any potential signal or concern. 
6 Vaccines Administered 
For proper management of the supply and accountability of the products, MenACYW conjugate vaccine and MENVEO
® will be considered  as Investigational Medicinal Product (IMP) and all 
other vaccines as Non -Investigational Medicinal Product (NIMP) . 
6.1 Identity of the Investigational Products 
6.1.1 Identity of Study  Product  
MenACYW conjugate vaccine:  Meningococcal Polysaccharide (Serogroups A, C, Y, and W) 
Tetanus Toxoid Conjugate Vaccine (Sanofi Pasteur Inc., Swiftwater, PA, USA) 
Form:    Liquid solution 
Dose:    0.5 milliliter (mL ) 
Route:    IM 
Batch number:  To be determined 
6.1.1.1 Composition  
Each 0.5 mL dos e of MenACYW conjugate vaccine is formulated in sodium acetate buffered 
saline solution to contain the following ingredients: 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 50 of 90
   
    
 
 
  
    Meningococcal capsular polysaccharides:  
Serogroup A  ........................................................................................ 10 micrograms (µg)  
Serogroup C ............................................................................................................... 10 µg  
Serogroup Y  ............................................................................................................... 10 µg  
Serogroup W  .............................................................................................................. 10 µg  
Tetan us toxoid protein carrier ..................................................................... approximately 55 µga 
6.1.1.2 Preparation and Administration  
MenACYW conjugate vaccine is supplied in single-dose vials (0.5 mL). 
Prior to administration, all study products must be inspected visually for cracks, broken seals, 
correct label content (see  Section 6.3.1),  and extraneous particulate matter and / or discoloration, 
whenever solution and container permit. If any of these conditions exists, the vaccine must not be administered. A replacement dose is to be used, and the event is to be reported to the Sponsor. 
The rubber stopper should not be removed from any of the vaccine vials. After vaccine administration, the used syringe and needle will be disposed of in accordance with 
currently established guidelines. Subjects must be kept under observation for 30 minutes after each vaccination to ensure their 
safety, and any reactions during this period will be documented in the CRB. Appropriate medical equipment and emergency medications, including epinephrine (1:1000), must be available on site in the event of an anaphylactic, vasovagal, or other immediate allergic reaction.  
6.1.1.3 Dose Selection and Timing  
Subjects i n Group 1 will receive MenACYW conjugate vaccine at 2, 4, 6, and 12 months of age. 
6.1.2 Identity of Control Product  
MENVEO
®: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM 197 
Conjugate Vaccine ( GlaxoSmithKline Vaccines, Srl, Bellaria-Rosia 53018, Sovicille [ SI], Italy)  
Form:    Lyophilized powder and liquid components are combined to produce a 
Solution for Intramuscular Injection 
Dose:    0.5 mL  
Route:    IM 
Batch number:  To be determined 
                                                 
aTetanus toxoid protein quantity is approximate and dependent on the polysaccharide -to-protein ratio for the 
conju gates used in each formulation.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 51 of 90
   
    
 
 
  
    6.1.2.1 Composition  
Each 0.5 mL dose of vaccine contain s the following active ingredients:  
MenA oligosaccharide  ............................................................................................ 10 mcg 
MenC oligosaccharide  .............................................................................................. 5 mcg 
MenY oligosaccharide  .............................................................................................. 5 mcg 
MenW -135 oligosaccharide ...................................................................................... 5 mcg 
CRM 197 protein ........................................................................................ 32.7 to 64.1 mc g 
Other ingredients per 0.5 mL dose: residual formaldehyde  ........................................ ≤ 0.30 mc g 
6.1.2.2 Preparation and Administration  
MENVEO® is supplied in 2 vials, a lyophilized MenA conjugate vaccine component to be 
reconstituted with the accompanying MenCYW-135 liquid conjugate component. A single dose 
after reconstitution is 0.5 mL. See the MENVEO® package insert  (37).  
The procedures for administering the control product are the same as those described for the trial product in Section 6.1.1.2. Each 0.5 mL dose
 is to be injected IM as indicated in the Operating 
Guidelines and Section 5.1.4. 
6.1.2.3 Dose Selection and Timing  
Subjects in Group 2 will receive MENVEO® at 2, 4, 6, and 12 months of age. 
6.2 Identity of Other Products  
6.2.1 Identity of Other Product 1  
Pentacel®: (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated 
Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine (Sanofi Pasteur 
Ltd, Toronto, Ontario, Canada) 
Form:    Liquid DTaP-IPV used to reconstitute lyophilized ActHIB® 
Dose:    0.5 mL  
Route:    IM 
Batch number:  To be determined 
6.2.1.1 Composition  
Each 0.5 mL dose contains: 
Diphtheria toxoid .................................................................... 15 Limit of Flocculation (Lf) 
Tetanus toxoid ................................................................................................................ 5 Lf 
Acellular pertussis antigens:  
Pertussis toxin (PT)  ................................................................................................ 20 µg 
Filamentous hemagglutinin (FHA)  ......................................................................... 20 µg 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 52 of 90
   
    
 
 
  
    Pertactin (PRN) ........................................................................................................ 3 µg 
Fimbriae Types 2 and 3 (FIM) ................................................................................. 5 µg 
Inactivated polioviruses:  
Type 1 (Mahoney) .................................................................... 40 D-antigen units (DU) 
Type 2 (MEF-1) ...................................................................................................... 8 DU  
Type 3 (Saukett) ................................................................................................... 32 DU 
H. influenzae  type b (PRP) ........................................................................................... 10 µg 
Tetanus toxoid (PRP- T) ................................................................................................ 24 µg 
Excipients:  
Alum inum phosphate (0.33 mg aluminum) (adjuvant) .............................................. 1.5 mg  
Polysorbate 80 ............................. approximately 10 parts per million (ppm ) by calculation 
Sucrose ..................................................................................................................... 42.5 mg  
Residual formaldehyde ............................................................................................... ≤ 5 µg Residual glutaraldehyde ............................................................................................ < 50 ng Residual bovine serum albumin ................................................................................. ≤ 50ng 2-phenoxyethanol ..................................................................................... 3.3 mg (0.6% v/v) Neomycin  ................................................................................................. < 4 picogram (pg) 
Polymyxin B sulfate .................................................................................................... < 4 pg 
6.2.1.2 Preparation and Administration  
Pentacel
® is supplied as a liquid vaccine component (DTaP- IPV component) that is combined 
through reconstitution with a lyophilized vaccine component (ActHIB vaccine), both in single dose vials. A single dose after reconstitution is 0.5 mL. See the Pentacel
® package insert  (42).  
The procedures for administering the product are the same as those described in Section 6.1.1.2. 
Each 0.5 mL dose is to be injected IM as indicated in the Operating Guidelines and Section 5.1.4.  
6.2.1.3 Dose Selection and Timing  
All s ubjects will receive Pentacel® at 2, 4, and 6 months of age. 
6.2.2 Identity of Other Product 2  
PREVNAR  13®: Pneumococcal 13 -valent Conjugate Vaccine (Diphtheria CRM 197 Protein) 
(Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc, Philadelphia, PA, USA) 
Form:    Suspension for injection  
Dose:    0.5 mL  
Route:    IM 
Batch number:  To be determined 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 53 of 90
   
    
 
 
  
    6.2.2.1 Composition  
Each 0.5 mL dose of the vaccine is formulated to contain:  
Streptococcus pneumoniae  serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F 
saccharides  .............................................................................. approximately 2.2 μg of each 
6B saccharides ............................................................................................................. 4.4 μg 
Excipients:  
CRM 197 carrier protein  ................................................................................................. 34 μg 
Polysorbate 80 ............................................................................................................ 100 μg 
Succinate buffer  .......................................................................................................... 295 μg 
Aluminum as aluminum phosphate adjuvant ............................................................. 125 μg 
6.2.2.2 Preparation and Administration  
PREVNAR 13® is supplied in a single- dose prefilled syringe.  See the PREVNAR 13® package 
insert  (43).  
The procedures for administering the product are the same as those described in Section 6.1.1.2. 
Each 0.5 mL dose is to be injected IM as indicated in the Operating Guidelines and Section 5.1.4.  
6.2.2.3 Dose Selection and Timing  
All subjects will receive PREVNAR 13® at 2, 4, 6, and 12 months of age. 
6.2.3 Identity of Other Product 3  
RotaTeq®: (Rotavirus Vaccine, Live, Oral, Pentavalent) (Merck Sharp & Dohme Corp., a 
subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA) 
Form:    Oral solution  
Dose:    2 mL 
Route:    Oral 
Batch number:  To be determined 
6.2.3.1 Composition  
Each 2 mL dose contains the following 5 live reassortant rotaviruses: 
G1 serotype ............................................................................ 2.2 x 106 infectious units (IU)  
G2 serotype ........................................................................................................ 2.8 x 106 IU 
G3 serotype ........................................................................................................ 2.2 x 106 IU 
G4 serotype ........................................................................................................ 2.0 x 106 IU 
P1A(8) ............................................................................................................... 2.3 x 106 IU 
The reassortants are suspended in a buffered stabilizer solution.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 54 of 90
   
    
 
 
  
    Each 2 mL vaccine dose also contains sucrose, sodium citrate, sodium phosphate monobasic 
monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal 
bovine serum. 
6.2.3.2 Preparation and Administration  
RotaTeq® is supplied in a container consisting of a squeezable plastic dosing tube with a twist- off 
cap, allowing for dire ct oral administration.  See the RotaTeq® package insert  (44).  
The procedures for administering the product are the same as those described in  Section 6.1.1.2 
Each 2 mL dose is to be administered orally, as indicated in the Operating Guidelines and 
Section  5.1.4. 
6.2.3.3 Dose Selection and Timing  
All subjects will receive RotaTeq® at 2, 4, and 6 months of age. 
6.2.4 Identity of Other Product 4  
ENGERIX-B®: (Hepatitis B Vaccine [Recombinant]) (GlaxoSmithKline Biologicals 441 
Rixensart, Belgi um) 
Form:    Suspension for injection  
Dose:    0.5 mL  
Route:    IM 
Batch number:  To be determined 
6.2.4.1 Composition  
Each 0.5 mL pediatric/adolescent dose contains 10 µg of hepatitis B virus surface antigen (HBsAg) adsorbed on 0.25 mg aluminum as aluminum hydroxide. 
Excipients:  
Sodium chloride ..................................................................................................... 9 mg/mL  
Disodium phosphate dihydrate .......................................................................... 0.98 mg/mL  
Sodium dihydrogen phosphate dihydrate .......................................................... 0.71 mg/mL  
6.2.4.2 Preparation and Administration  
ENGERIX-B
® is supplied as 0.5 mL prefilled syringes. See the ENGERIX -B® package insert  
 (45). The procedures for administering the product are the same as those described in  Section 6.1.1.2. 
Each 0.5 mL dose is to be injected IM, as indicated in the Operating Guidelines and Section 5.1.4. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 55 of 90
   
    
 
 
  
    6.2.4.3 Dose Selection and Timing  
All subjects will receive ENGERIX -B® at 2 and 6 months of age. 
Note:  The first dose of hepatitis B vaccine must be given at least 28 days prior to study 
enrollment. 
6.2.5 Identity of Other Product 5 
M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live) (Merck Sharp & Dohme Corp., a 
subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA) 
Form:  Lyophilized live virus vaccine 
Dose:    0.5 mL  
Route:    SC 
Batch number:  To be determined 
 
6.2.5.1 Composition  
Each 0.5 mL dose contains live attenuated virus: 
Measles virus (derived from Ender’s Edmonston strain) propagated in chick embryo cell 
culture  ............................................................................................ not less than 1000 TCID 50a 
Mumps virus (Jeryl Lynn™ [B level] strain) propagated in chick embryo cell culture  
 .................................................................................................... not less than 12,500 TCID 50a 
Rubella virus (Wistar RA 27/3 strain) propagated in WI-38 human diploid lung fibroblasts  ....................................................................................................... not less than 1000 TCID
50a 
Each 0.5 mL dose is calculated to contain sorbitol (14.5 mg), sodium phosphate, sucrose (1.9 mg), sodium chloride, hydrolyzed gelatin (14.5 mg), recombinant human albumin (≤ 0.3 mg), fetal bovine serum (< 1 ppm), other buffer and media ingredients and approximately 25 µg of neomycin. 
6.2.5.2 Preparation and Administration  
M-M-R
® II is supplied as a lyophilized vaccine to be reconstituted using the accompanying sterile 
diluent.  See the M-M-R® II package insert  (46).  
The procedures for administering the product are the same as those described in  Section 6.1.1.2. 
Each 0.5 mL dose is to be injected SC in the outer aspect of the upper arm as indicated in the 
Operating Guidelines and Section 5.1.4. 
                                                 
a  TCID 50 = tissue culture infectious  doses 50%  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 56 of 90
   
    
 
 
  
    6.2.5.3 Dose Selection and Timing  
All subjects will receive M -M-R® II at 12 months of age. 
6.2.6 Identity of Other Product 6 
VARIVAX®: Varicella Virus Vaccine Live (Merck Sharp & Dohme Corp., a subsidiary of Merck 
& Co., Inc., Whitehouse Station, NJ, USA)  
Form:    Suspension for injection  
Dose:    0.5 mL  
Route:    SC 
Batch number:  To be determined 
6.2.6.1 Composition  
Each approximately 0.5 mL dose contains: 
Live, attenuated Oka/Merck varicella virus  ........ at least 1350 plaque-forming units (PFU) 
Excipients:  
Sucrose ........................................................................................................................ 25 mg  
Hydrolyzed gelatin  ................................................................................................... 12.5 mg  
Sodium chloride ......................................................................................................... 3.2 mg  
Monosodium L- glutamate  .......................................................................................... 0.5 mg  
Sodium phosphate dibasic ........................................................................................ 0.45 mg  
Potassium phosphate monobasic .............................................................................. 0.08 mg  
Potassium chloride .................................................................................................... 0.08 mg  
The vaccine contains residual components of MRC -5 cells including DNA and protein and trace 
quantities of sodium phosphate monobasic, EDTA, neomycin, and fetal bovine serum. The 
vaccine contains no preservative. 
6.2.6.2 Preparation and Administration  
VARIVAX® is supplied as a lyophilized vaccine to be reconstituted using the accompanying 
sterile diluent.  See the V ARIVAX® package insert  (47).  
The procedures for administering the product are the same as those described in Section 6.1.1.2. 
Each 0.5 mL dose is to be injected SC into the outer aspect of the upper arm, as indicated in the 
Operating Guidelines  Section 5.1.4.  
6.2.6.3 Dose Selection and Timing  
All subjects will receive VARIVAX® at 12 months of age. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 57 of 90
   
    
 
 
  
    6.3 Product Logistics  
6.3.1 Labeling and Packaging 
The investigational product, MenACYW conjugate vaccine (single-dose vials), and control 
product will be supplied with investigational labeling and packaging according to national regulations. Each single dose of investigational or control product will be identified by a unique number on the detachable label and on the outer carton label. The carton label will also have a detachable label for the sites to attach to the source documents. See the Operating Guidelines for additional label detail.  
The investigat ional and control products are blinded at the level of the carton .  
All of the concomitant products will retain original commercial labeling and packaging with no additional labels to be applied. 
The concomitant products (licensed routine vaccines) are not  blinded. 
6.3.2 Product Shipment, Storage, and Accountability  
6.3.2.1 Product Shipment  
The Clinical Logistics Coordinator or designee will contact the Investigator or a designee to 
determine the dates and times of delivery of products. Each vaccine shipment will include a temperature-monitoring device to verify maintenance of the 
cold chain during transit. On delivery of the product to the site, the person in charge of product receipt will follow the instructions given in the Operating G uidelines, including checking that the 
cold chain was maintained during shipment (i.e., verification of the temperature recorders). If there is an indication that the cold chain was broken, this person should immediately quarantine the product, alert the S anofi Pasteur  representative, and request authorization from Sanofi Pasteur  
to use the product. 
6.3.2.2 Product Storage  
The Investigator will be personally responsible for product management or will designate a staff 
member to assume this responsibility.  
At the site, products must be kept in a secure place with restricted access. The Study and Control 
Products (MenACYW conjugate vaccine or MENVEO
®) will be stored in a refrigerator at a 
temperature ranging from +2°C to +8°C and never frozen. All commercially labeled products should be stored according to the manufacturer’s instructions. The temperature must be monitored and documented (see the Operating Guidelines) for the entire time that the vaccine is at the study  
site. In case of accidental freezing or disruption  of the cold chain, vaccines must not be 
administered and must be quarantined, and the Investigator or authorized designee should contact the Sanofi Pasteur  representative for further instructions.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 58 of 90
   
    
 
 
  
    6.3.2.3 Product Accountability  
The person in charge of product management at the site will maintain records of product delivery 
to the study site, product inventory at the site, the dose given to each subject, and the disposal of 
or return to the Sponsor of unused doses. 
The necessary infor mation on the product labels is to be entered into the source document and the 
CRB. If applicable, information may also be entered into the subject’s vaccination card. The Sponsor’s monitoring staff will verify the study  site’s product accountability recor ds against 
the record of administered doses in the CRBs and the communication from the IRT  system  (if 
applicable). In case of any expected or potential shortage of product during the study, the Investigator or an 
authorized designee should alert the Sanofi Pasteur  representative as soon as possible, so that a 
shipment of extra doses can be arranged.  
6.3.3 Replacement Doses 
If a replacement dose is required (e.g., because the syringe broke or particulate matter was observed in the syringe), the site personnel must either contact the IRT system to receive the new 
dose allocation, or follow the instructions given in the Operating Guidelines. 
6.3.4 Disposal of Unused Products  
Unused or wasted products will be returned to the Sponsor in accordance with the instructions in 
the Operating Guidelines. Product accountability will be verified throughout the study period. 
6.3.5 Recall of Products  
If the Sponsor makes a decision to launch a retrieval procedure, the Investigator(s) will be informed of what needs to be done. 
6.4 Blinding and Code- breaking Procedures  
This trial is a modified double -blind trial, which means that the subject’s parent / guardian, the 
Investigator, and other study personnel remain unaware of the treatment assignments throughout the trial. An unblinded vaccine administ rator will administer the appropriate vaccine but will not 
be involved in safety data collection. The Sponsor will also remain blinded to treatment assignments throughout the trial until database lock. 
The code may be broken in the event of an AE only when the identification of the vaccine 
received could influence the treatment of the subject. Code-breaking should be limited to the subject(s) experiencing the AE.  
• The blind can be broken by the Investigator or a delegate through the IRT system, as 
explained in the code-breaking procedures described in the Operating Guidelines. Once the 
emergency has been addressed by the site, the Investigator or a delegate must notify the 
Sanofi Pasteur RMO if a subject’s code was broken. All contact attempts with the Sponsor 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 59 of 90
   
    
 
 
  
    prior to unblinding are to be documented in the source documents, and the code breaking CRF 
is to be completed. 
A request for the code to be broken may also be made:  
• by the GP V Department through an internal  system for reporting to health authorities in the 
case of an SAE as described in  International Conference on Harmonisation  (ICH) E2A. In this 
case, the code will be broken only for the subject(s) in question. The information resulting 
from code-breaking (i.e., the subject’s vaccine or group assignment ) will not be 
communicated to either the Investigator or the immediate team working on the study, except for the GPV representative . 
The IEC  / IRB must be notified of the code-breaking. All documentation pertaining to the event 
must be retained in the site ’s study records and in the Sanofi Pasteur  files. Any intentional or 
unintentional code-breaking must be reported, documented, and explained, and the name of the person who requested it must be provided to the Sponsor. 
6.5 Randomization and Allocation Procedur es 
On the day of enrollment, subjects who meet the inclusion/exclusion criteria and whose parent / guardian signs the ICF will be randomly assigned to Group 1 or Group 2 in a 3:1 ratio such that 
Group 1 will have approximately 2310 subjects and Group 2 will have approximately 
770 subjects.  
Site staff will connect to the IRT  system , enter the identification and security information, and 
confirm a minimal amount of data in response to IRT system prompts. The IRT system will then 
provide the vaccine assignm ent and subject number. The full detailed procedures for group 
allocation are described in the Operating Guidelines. If the subject is not eligible to participate in the study, then the information will only be recorded on the subject recruitment log. 
Subject numbers that are assigned by the IRT system  will consist of a 12- digit string (a 3 -digit 
country identifier, a 4 -digit study center identifier , and a 5- digit subject identifier). For example, 
Subject 840000100005 is the fifth subject enrolled in C enter  Number  1 in the US (840 being the 
US country code). 
Subject numbers should not be reassigned for any reason. The randomization codes will be kept 
securely in the IRT  system . 
6.6 Treatment Compliance  
The following measures will ensure that the vaccine doses administered comply with those planned, and that any non- compliance is documented so that it can be accounted for in the data analyses:  
• All vaccinations will be administered by qualified study perso nnel 
• The person in charge of product management at the site will maintain accountability records 
of product delivery to the study site, product inventory at the site, dose(s) given to each subject, and the disposal of unused or wasted doses 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 60 of 90
   
    
 
 
  
    6.7 Concomitant Medications  and Other Therapies  
At the time of enrollment, ongoing medications including but not limited to other therapies (e.g., 
blood products), should be recorded in the source documents. All new medications prescribed for new medical conditions / AEs during study participation should also be recorded in the source documents.  
Documentation in the CRB of concomitant medication(s) will be limited to specific categories of 
medication(s) (Categories 1  and 2 as detailed below). Those will include Category 1 and  2 
medications ongoing at the time of inclusion in the study, or started at any time during the subject’s participation in the trial.  
Collection Period in S ource D ocuments  
Reportable medications (Category 1 and 2) will be collected in the source documents from the day of first vaccination to the end of the trial
a. 
Categories of Reportable Medications and Reporting P eriod  
Reportable medications include medications that impact or may impact the consistency of the safety information collected after any vac cination and/or the immune response to vaccination.   
Category 1: Reportable medications with potential impact on the evaluation of the safety of the 
study vaccines. For example, antipyretics, analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), syst emic corticosteroids (therapy duration less than 2 weeks) , and other immune 
modulators. 
Note: Topical steroids ( inhaled, otic, ophthalmic, nasal, etc.) should not be captured or reported. 
• Category 1 medications will be reported in the CRB from the day of f irst vaccination to 
the end of the solicited and unsolicited follow-up period after each vaccination. These medications will also be collected in the CRB for the 30 -day period prior to the 
subsequent doses of the vaccine, wherever applicable (second, third , fourth, etc., in case 
of a multi-dose schedule with more than a 30-day interval between doses). 
• Category 2: Reportable medications with potential impact on immune response of the study 
vaccines and used to define the Per -Protocol Analysis Set (PPAS). For example:  
• Influenza and other non- study vaccines: Influenza vaccine in the 2  weeks (14 days) 
preceding the trial vaccination up to the last study visit and any other vaccines (other than 
the study vaccine) in the 4 weeks preceding the trial vaccination up to the last study visit 
• Immune globulins, blood, or blood-derived products: used in the 3 months preceding the first  trial vaccination  and up to the last study visit 
• Immunosuppressive therapy such as immune-suppressors, immune-modulators with 
immunosuppressive properties, long- term systemic corticosteroids therapy (prednisone or 
equivalent for more than 2 consecutive weeks) within past 3 months, anti- cancer 
                                                 
a  Subject’s parents will be required to document all medications received in the Diary Cards. The sites will focus on 
only recording the medications belonging to the 2 categories in the other source documents.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 61 of 90
   
    
 
 
  
    chemotherapy, anti-proliferative drugs such as DNA synthesis inhibitors, or radiation 
therapy: used in the 6 months preceding the first trial vaccination, and up to the last study 
visit. 
o Category 2 medications will be reported in the CR B according to the collection 
period detailed above up to the last  study visit. 
The information reported in the CRB for each reported medication will be limited to: 
• Trade name 
• Rationale for the origin of prescription: Whether it was a prophylactica medicat ion. 
Prophylactic medications will be recorded in the Action Taken section of the AE collection 
tables.  
• Medication category (1  or 2) 
• Start and stop dates  
Dosage and administration route, homeopathic medication, will not be recorded. 
If the subject has received medications other than those listed in Categories 1 or 2, the detailed 
information will be collected  in the source documents only. 
Medications given to treat an AE will be captured in the “Action Taken” section of the AE CRB only. No details will be r ecorded in the concomitant medication CRB unless the medication(s) 
received belongs to one of the prelisted categories.  
7 Management of Samples  
This is a safety study; no blood samples will be collected.  
8 Clinical Supplies  
Sanofi Pasteur will supply the study sites with p rotocols, ICFs, CRBs , SAE reporting forms, diary 
cards, memory aids, and other study documents, as well as with the following study materials: all 
study vaccines, temperature recorders, shipping containers, rulers, and digital thermometers.  
The means for performing Electronic Data Capture (EDC) will be defined by Sanofi Pasteur . If a 
computer is provided by Sanofi Pasteur , it will be retrieved at the end of the study. 
The Investigator will supply all vaccination supplies, including biohazard and / or safety supplies. 
The biohazard and safety supplies include needles and syringes, examination gloves, laboratory coats, sharps disposal containers, and absorbent countertop paper. The site will ensure that all biohazard wastes are autoclaved and disposed of in accordance with local practices. The 
                                                 
a  Medication(s) prescribed for preventing AE occurrence (e.g. paracetamol to reduce the risk of fever)  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 62 of 90
   
    
 
 
  
    Investigator will also supply appropriate space in a temperature- monitored refrigerator for the 
storage of the products. Please see Operating Guidelines for further details.  
In the event that additional sup plies are required, study staff must contact Sanofi Pasteur , 
indicating the quantity required. Contact information is provided in the Operating Guidelines. 
They must allow approximately 1 week for an order to be filled and to have the supplies sent to their site.  
9 Endpoints and Assessment Methods  
9.1 Observational E ndpoints and Assessment Methods  
9.1.1 Safety   
9.1.1.1 Safety Definitions  
The following definitions are taken from the ICH E2A Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. 
Adverse Event (AE):  
An AE is any untoward medical occurrence in a patient or in a clinical investigation subject 
administered a medicinal product and which does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.  
Therefore an AE may b e: 
• A new illness  
• The worsening of a pre- existing condition  
• An effect of the vaccination, including the comparator 
• A combination of the above 
All AEs include serious and non- serious AEs. 
Surgical procedures are not AE s; they are the action s taken to treat a medical condition. It is the 
condition leading to the action taken that is the AE  (if it occurs during the study period). 
Pre-existing medical conditions are not to be reported as AEs. However, if a pre- existing medical 
condition worsens following study interventions in frequency or intensity, or if according to the 
Investigator there is a change in its clinical significance, this change should be reported as an AE 
(exacerbation). This applies equally to recurring episodes of pre-existing conditions (e.g., asthma) if the frequency or intensity increases post -vaccination. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 63 of 90
   
    
 
 
  
    Serious Adverse Event (SAE):  
Serious  and severe are not synonymous. The term severe is often used to describe the intensity of 
a specific event as corresponding to Grade  3. This is not the same as serious which is based on 
subject / event outcome or action criteria usually associated with events that pose a threat to a 
subject’s life or functioning. Seriousness, not severity, serves as a guide for defining regulatory reporting obligations. 
An SAE is any untoward medical occurrence that at any dose  
• Results in death  
• Is life -threatening
a 
• Requires inpatient hospitalization or prolongation of existing hospitalizationb 
• Results in persistent or significant disability  / incapacityc 
• Is a congenital anomaly  / birth defect  
• Is an important medical event  (IME) 
Medical and scientific judgment should be exercised in deciding whether expedited reporting 
is appropriate in other situations, such as IME s that may not be immediately life -threatening 
or result in death or hospitalization but may jeopardize the health of the subject or may require intervention to prevent one of the other outcomes listed in the definition above. These IMEs should also usuall y be considered serious. Examples of such events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse, new- onset diabetes, or autoimmune disease.  
Adverse Reaction:  
All noxious and unintended responses to a medicinal product related to any dose should be considered AR. 
(The phrase “responses to a medicinal product” means that a causal rel ationship between a 
medicinal product and an AE  is at least a reasonable possibility)  
                                                 
a  The term “life -threatening” refers to an event in which the subject  was at risk of death at the time of the event; it 
does not refer to an event which hypothetically might have caused death if it were more severe.  
b  All medical events leading to hospitalizations will be recorded and reported as SAEs , with the exception of: 
hospitalization planned before inclusion into the study or outpatient  treatment with no hospitalization.  
c  “Persistent or significant disability or incapacity” means that there is a substantial disruption of a person’s ability 
to carry out normal life functions.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 64 of 90
   
    
 
 
  
    The following additional definitions are used by Sanofi Pasteur: 
Immediate Event/Reaction : 
Immediate events are recorded to capture medically relevant unsolicited systemi c AEs (including 
those related to the product administered) that occur within the first 30 minutes after vaccination.  
Solicited Reaction:  
A solicited reaction is an “expected” AR (sign or symptom) observed and reported under the 
conditions (nature and onse t) pre -listed in the protocol and CRB. 
Examples of solicited reactions include  injection site tenderness or irritability  occurring between 
D0 and D07 after vaccination. 
By definition, solicited reactions are to be considered as being related to the product administered.  
For injectable vaccines, solicited reactions can either be solicited injection site reactions or 
solicited  systemic reactions. 
The assessment of these reactions by the Investigator is mandatory.  
Unsolicited AE / AR:  
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. For example, if vomiting  between D0 
and D07 is a solicited reaction (i.e., pre -listed in the protocol and CRB), then vomiting starting on 
D07 is a solicited reaction, whereas vomiting starting on D08 post-vaccination is an unsolicited 
AE. Unsolicited AEs includes both serious (SAEs) and non- serious unsolicited AEs.  
Injection Site Reaction:  
An injection site reaction is an AR at and around the injection site. Injection site reactions are commonly inflammatory reactions. They are considered to be related to the product administered. 
Systemic AE:  
Systemic AEs are all AEs that are not injection or administration site reactions. They therefore 
include systemic manifestations such as vomiting, fever, as well as localized or topical 
manifestations that are not associated with the vaccination or administration site (e.g., erythema 
that is localized but that is not occurring at the injecti on site).  
Adverse Event of Special Interest (AESI):  
An AESI is an event for which ongoing monitoring and rapid communication by the Investigator to the Sponsor must be done. 
Such an event might warrant further investigation in order to characterize and understand it. 
Depending on the nature of the event, rapid communication by the study Sponsor to other parties (e.g., regulators) might also be warranted. 
Medically -Attended Adverse Event (MAAE)  
An MAAE is defined, for the purpose of this study, as a new onset of a condition that prompts the 
subject or subject’s parent/guardian to seek unplanned medical advice at a health care provider’s office or Emergency Department. This definition excludes pre- planned medical office visits for 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 65 of 90
   
    
 
 
  
    routine pediatric check -ups or follow -up visits of chronic conditions with an onset prior to entry in 
the study. Health care provider contact made over the phone or by email will be considered a 
physician office visit for the purpose of MAAE collection. The outcome of the health care provider contact (whether it results in a prescription or not) will not be considered as a basis for reporting the event as an MAAE and all contacts should be reported. Sufficient data should be collected for the event to allow an assessment of the causali ty and diagnosis, if possible.  
 
9.1.1.2 Safety Endpoints  
The endpoints for the evaluation of safety are : 
• Occurrence, nature (Medical Dictionary for Regulatory Activities [MedDRA] preferred 
term), duration, intensity, and relationship to vaccination, and whether the event led to 
early termination from the study, of any unsolicited systemic AEs reported in the 30 minutes after each vaccination.  
• Occurrence, time of onset, number of days of occurrence, intensity, action taken, and 
whether the reaction led to early termination from the study, of solicited (prelisted in the subject’s diary card and CRB) injection site reactions occurring up to D07 after each 
vaccination. 
• Occurrence, time of onset, number of days of occurrence, intensity, action taken, and 
whether the re action led to early termination from the study, of solicited (prelisted in the 
subject’s diary card and CR B) systemic reactions occurring up to D 07 after each 
vaccination. 
• Occurrence, nature (MedDRA preferred term), time of onset, duration, intensity, acti on 
taken, relationship to vaccination, and whether the event led to early termination from the study, of unsolicited AEs up to D30 after each vaccination. 
• Occurrence, nature (MedDRA preferred term), time of onset, duration, seriousness criteria, 
relationsh ip to vaccination, outcome, and whether the event led to early termination from 
the study, of SAEs (including AESIs) throughout the trial from Visit 1 to the 6-month follow-up conta ct after the last vaccination . 
• Occurrence, nature (MedDRA preferred term), time of onset, duration, intensity, action 
taken, relationship to vaccination (), and whether the event led to early termination from the study for MAAEs throughout the trial, from Visit 1 to the 6-month follow-up contact after the last vaccination.  
9.1.1.3 Safet y Assessment Methods 
At each vaccination visit, the Investigator or a delegate will perform a physical examination on 
the basis of relevant medical history according to the Investigator’s clinical judgment and will ask 
the parent / guardian about any solic ited reactions and unsolicited AEs recorded in the diary card, 
as well as about any other AEs that may have occurred since the previous visit. All relevant data will be transcribed into the CRB according to the instructions provided by the Sponsor. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 66 of 90
   
    
 
 
  
    9.1.1.3.1 Immedia te Post-vaccination Observation Period  
Subjects will be kept under observation for 30 minutes after each vaccination to ensure their 
safety. The post -vaccination observation should be documented in the source document. Any AE 
that occurs during this period  will be noted on the source document and recorded in the CRB, as 
follows: 
• Unsolicited s ystemic AEs will be recorded as immediate AEs in the CRB (presence marked as 
“yes” and details collected) . 
• Solicited and unsolicited injection site reactions and solicited systemic reactions will be 
recorded in the CRB in the same way as any reactions starting on the day of vaccination.  
• SAE s will be recorded in the CRB and reported to the Sponsor in the same way as any other 
SAE s, according to the procedures described in Section 10.  
9.1.1.3.2 Reactogenicity (Solicited Reactions From Day 0 to Day  7 After Each 
Vaccination) 
After  the first  vaccination, parents / guardians will be provided with a diary card, a digital 
thermometer, and a flexible ruler, and will be instructed how to use them. T he following items 
will be recorded by the subject’s parent / guardian in the diary card on the day of vaccination and 
for the next 7 days (i.e., D0 to D07) until resolution : 
• Daily temperature, with the route by which it was taken 
• Daily measurement or intensity grade of all other solicited injection site and systemic 
reactions  
• Action taken for each event (e.g., medication) 
The action (s) taken by the parent or guardian  to treat and/or manage any solicited reactions  
will be classified in the CRB using the following list (all applicable items should be 
checked) : 
• None 
• Medication  
• Health care provider contact  
• Hospitalized  
• Discontinuation of study vaccination 
Parents / guardians will be contacted by telephone 8 days after each  vaccination to remind them to 
record all safety information in the diary card.  
If the timing of the telephon e call should fall on a weekend or a holiday, the call should be made 
on the next business day. If contact is not made on the designated day, study  staff will continue 
calling until contact is made. Every telephone attempt and its outcome will be documente d in the 
source document. 
Table 9.1 a nd Table 9.2 present, respectively, the injection site reactions and systemic reactions 
that are prelisted in the diary cards and CRB, together with the intensity scales.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 67 of 90
   
    
 
 
  
    Table 9.1: Solicited injection site reactions: terminology , definitions , and intensity scales  
CRB term  
(MedDRA 
lowest level 
term [LLT])  Injection site tenderness  Injection site erythema  Injection site swelling  
MedDRA 
preferred 
term  Injection site pain Injection site erythema  Injection site swelling 
Diary card 
term  Tenderness  Redness  Swelling  
Definition Pain when the injection site 
is touched or injected limb 
mobilized  Presence of a redness 
including the approximate 
point of needle entry Swelling at or near the 
injection site  
Swelling or edema is caused by a fluid infiltration in 
tissue or cavity and, 
depending on the space 
available for the fluid to disperse, swelling may be either soft (typically) or firm 
(less typical) to touch and 
thus can be best described by looking at the size of the 
swelling  
Intensity scale*  Grade 1: Minor reaction 
when injection site is 
touched 
Grade 2: Cries or protests 
when injection site is 
touched 
Grade 3: Cries when injected 
limb is mobilized, or the 
movement of the injected limb is reduced  Grade 1: > 0 to <  25 mm  
Grade 2: ≥ 25 to <  50 mm  
Grade 3: ≥ 50 mm Grade 1: > 0 to <  25 mm  
Grade 2: ≥ 25 to <  50 mm  
Grade 3: ≥ 50 mm 
*  For the subjective reaction of tenderness, parents / guardians will record the intensity level (Grade  1, 2, or 3) in the 
diary card. For the measurable reactions of redness and swelling, they will record just the size of the reaction, and 
the classification as Grade  1, 2, or 3 will be assigned at the time of the statistical analysis.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 68 of 90
   
    
 
 
  
    Table 9.2: Solicited systemic reaction s: terminology , definitions , and intensity scales  
CRB term 
(MedDRA 
LLT) Fever  Vomiting  Crying 
abnormal  Drowsiness  Appetite lost  Irritability  
MedDRA 
preferred 
term  Pyrexia  Vomiting  Crying Somnolence Decreased 
appetite  Irritability 
Diary card 
term  Temperature  Vomiting  Abnormal crying Drowsiness  Loss of appetite  Irritability 
Definition  Elevation of 
temperature to ≥°38.0°C  
(≥ 100.4°F ) Vomiting 
does not include spitting up  Inconsolable 
crying without a 
determined 
reason  Reduced 
interest in 
surroundings, 
or increased 
sleeping  See intensity 
scale  An excessive 
response to 
stimuli: 
increased 
fussiness, whining, and fretfulness despite attempts to 
comfort the 
infant and despite caregiver responses 
that would 
normally be 
soothing  
Intensity 
scale*  Grade 1:  
≥ 38.0°C to 
≤ 38.5°C  
or ≥ 100.4°F to 
≤ 101.3°F  Grade 1: 
1 episode per 
24 hours  Grade 1: 
< 1 hour Grade 1: 
Sleepier than 
usual or less 
interested in 
surroundings  Grade 1: 
Eating less 
than normal  Grade 1: 
Easily consolable  
 Grade 2: 
> 38.5°C to 
≤ 39.5°C  
or > 101.3°F 
to ≤ 103.1°F  Grade 2: 2–
5 episodes 
per 24 hours  Grade 2: 1–
3 hours  Grade 2: Not 
interested in surroundings or did not wake up for a feed / meal  Grade 2: 
Missed 1 or 2 feeds / meals 
completely  Grade 2: 
Requiring 
increased 
attention  
 Grade 3: 
> 39.5°C  
or > 103.1°F  Grade 3: 
≥ 6 episodes 
per 24 hours 
or requiring 
parenteral 
hydration  Grade 3: 
> 3 hours  Grade 3: 
Sleeping 
most of the 
time or difficult to 
wake up  Grade 3: 
Refuses ≥ 3 
feeds / meals 
or refuses most feeds / 
meals  Grade 3: 
Inconsolable  
*  For all reactions but fever,  parents / guardians will record the intensity level (Grade 1, 2, or 3) in the diary card. For fever, they 
will record the body temperature, and the classification as Grade  1, 2, or 3 will be assigned at the time of the statistical analysis  
based on the unit used to measure the temperature and the intensity scale . 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 69 of 90
   
    
 
 
  
    Important N otes for the A ccurate Assessment of Temperature:  
Parents / guardians are to measure body temperature once per day, preferably always at the same 
time. The optimal time for measurement is the evening, when body temperature is the highest. 
Temperature is also to be measured at the time of any apparent fever. The observed  daily 
temperature and the route of measurement are to be recorded in the diary card , and the highest 
temperature will be recorded by the site in the CRB. The preferred route for this study is rectal . 
Pre-vaccination temperature is also systematically collected  by the Investigator on the source 
document. Tympanic thermometers  or forehead skin thermometers must not be used. 
9.1.1.3.3 Unsolicited Adverse Events  
In addition to recording solicited reactions, parents / guardians will be instructed to record any 
other medical events that may occur during the 30-day period after  each vaccination . Space will 
be provided in the diary card for this purpose. 
Information on SAEs will be collected and assessed throughout the study, from the time of 
vaccination until 6 months after the last vaccination. Any SAE occurring at any time during the 
study will be reported by the Investigator in the CRB according to the completion instructions 
provided by the Sponsor; this includes checking the “Serious” box on the AE CRF and completing the appropriate Safety Complementary Information CRFs. All information concerning the SAE is to be reported either as part of the initial reporting or during follow -up reporting if 
relevant information became available later (e.g., outcome, medical history, resul ts of 
investigations, copy of hospitalization reports). In case a subject experiences febrile convulsion 
(neurological event associating fever and seizure), the assessment will be performed according to the “Guideline for definition and collection of cases of febrile convulsion”, and this event will be considered an SAE. See  Section 10 fo r further details on SAE reporting.  
For each unsolicited AE (whether serious or non-serious), the following information is to be 
recorded:  
• Start and stop dates
a  
• Intensity of the event: 
For measurable unsolicited AEs that are part of the list of solicited reactions, the size of the 
AE as well as the temperature for fever will be collected and analyzed based on the corresponding scale used for solicited reactions (see Table 9.1 and Table 9.2).  
All other unsolicited AEs will be classified according to the following intensity scale:  
• Grade  1: A type of AE  that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities of daily living.  
                                                 
a  The stop date of all related AEs will be actively solicited. For other events, the Investigator will provide the stop 
date when it becomes available. AEs for which no stop date was obtained during the course of the study will be 
considered as ongoing at the end of the study.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 70 of 90
   
    
 
 
  
    • Grade  2: A type of AE  that is usually alleviated with additional therapeutic inte rvention. 
The event interferes with usual activities of daily living, causing discomfort but poses no 
significant or permanent risk of harm to the research participant.  
• Grade  3: A type of AE  that interrupts usual activities of daily living, or significant ly affects 
clinical status, or may require intensive therapeutic intervention.  
• Whether the AE was related to the investigational product (for unsolicited systemic AEs) 
The Investigator will assess the causal relationship between the AE and the investigatio nal 
product as either “Not related” or “Related”, as described in  Section 9.1.1.3.6. 
Action taken for each AE (e.g., medication) 
The action(s) taken by the parent / guardian  to treat and/or manage any unsolicited AEs will 
be classified in the CRB using the following list (all applicable items should be checked): 
• None 
• Medication  
• Health care provider contact  
• Hospitalized  
• Discontinuation of study vaccination 
• Whether the AE was serious 
For each SAE, the I nvestigator will complete all seriousness criteria that apply (outcome, 
elapsed time, and relationship to study procedures). 
• Whether the AE caused study  discontinuation 
9.1.1.3.4 Adverse Events of Special Interest  
An AESI is defined as an event for which ongoing monitoring and rapid communication by the 
Investigator to the Sponsor must be done. The following AEs will be captured as AESIs 
throughout the study:  
• Generalized seizures (febrile and non -febrile) (48) (49) 
• Kawasaki disease (50) ( 51) (52) 
• Guillain -Barré syndrome  (53) 
• Idiopathic thrombocytopenic purpura (ITP) (54)  (55)  
These events have been listed as AESIs based on the feedback received from the European Union 
regulators.  
No safety concerns relating to these AESIs have been identified with the use of MenACY W 
conjugate vaccine in the completed clinical trials. Because of their medical importance and to ensure expedited communication to the Sponsor, these AESIs are to be considered and collected 
as SAEs and reported to the Sponsor according to the procedure de scribed in  Section 10 . Further 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 71 of 90
   
    
 
 
  
    instructions on the data collection for these events and the relevant definitions will be provided in 
the Operating Guidelines.  
9.1.1.3.5 Medically -Attended Adverse Events 
MAAE information will be collected throughout the study. MAAEs will be recorded  as 
unsolicited AEs for up to D30 after each vaccination  and as MAAEs until the next study visit on 
the appropriate diary cards. MAAEs that occur from D31 after the last vaccination visit until the 
6-month follow up phone call will be recorded in the appropriate memory aid. An MAAE that 
occurs within the study period but meets the definition of an SAE should be reported only on the SAE Repor ting Form but not on the MAAE page of the CRB . The Investigator will assess the 
causal relationship between the MAAE and the investigational or study product as either “Not related” or “R elated”, as described in  Section 9.1.1.3.6. 
9.1.1.3.6 Assessment of Causality  
The Investigator will assess the causal relationship  between each unsolicited systemic AE and 
the product administered as either  not related  or related , based on the following definitions: 
• Not related – The AE is clearly / most probably caused by other etiologies such as an  
underlying condition, therapeutic intervention, or concomitant therapy; or the delay between vaccination and the onset of the AE is incompatible with a causal relationship; or the AE started before the first vaccination (screening phase, if applicable) 
• Related – There is a “reasonable possibility” that the AE was caused by the product 
administered , meaning that there is evidence or arguments to suggest a causal relationship 
Note: By convention, all AEs reported at the injection site  (whether solicited or unsolicited) and 
all solicited systemic AEs are considered to be related to the administered product and therefore 
are referred to as reactions and do not require the Investigator’s opinion on relatedness. 
AEs likely to be related to the product, whether serious or not, that persist at the end of the study 
will be followed up by the Investigator until their complete disappearance or the stabilization of 
the subject’s condition. The Investigator will inform the Sponsor of the date of final disappearance of th e event or the date of “chronicity” establishment . 
9.2 Immunogenicity  
There are no objectives for immunogenicity in this study. 
9.3 Efficacy 
There are no objectives for efficacy  in this study. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 72 of 90
   
    
 
 
  
    10 Reporting of Serious Adverse Events  
To comply with current regulations on SAE reporting to health authorities, the Investigator must 
document all SAEs regardless of causal relationship, and notify the Sponsor and the Clinical Research Associate ( CRA) within the notification timelines stated in the following sections. The 
Investigator will give access and provide the Sponsor and the CRA with all necessary information to allow the Sponsor to conduct a detailed analysis of the safety of the investigational product(s). It is the responsibility of the Investigator to request all necessary documentation (e.g., medical 
records, discharge summary ) in order to provide comprehensive safety information. All relevant 
information must then be transcribed onto the AE CRF and the appropriate Safety Complement ary Information CRFs. 
10.1 Initial Reporting by the Investigator  
SAEs  occurring during a subject’s participation in the study or experiment must be reported 
within 24 hours to the Sponsor’s GP V Department and to the CRA. Every SAE must be reported, 
even if the Investigator considers that it is not related to the vaccine. The Investigator (licensed 
physician [M.D. or D.O.]) must validate the information entered on the AE CRF by completing the Investigator validation form. 
The Investigator must indicate on the AE CRF that the event was serious and must complete the 
relevant SAE section of this form as well as the appropriate Safety Complementary Information CRFs. An e -mail alert will automatically be sent by the EDC system to the GPV mailbox, the 
CRA and the RMO wi th relevant SAE information details.  
If the EDC system is unavailable, the site must notify the Sponsor, using the paper version of the CRB, as described in the operating guidelines: 
The Investigator must complete the paper copies of the AE CRF and of the appropriate Safety 
Complementary Information CRFs  and send them to the Sponsor by one of the following means: 
• By fax, to the following number:570-957-2782 
• In PDF format to the following e-mail address, using a method of transmission that 
includes password protection: PV.outsourcing@sanofi.com 
• By express mail, to the following address:  
Sanofi Pasteur Inc. 
Reception and Triage – Case Management  
Global PharmacoVigilance Mail Drop: 45D38 Discovery Drive Swiftwater, PA 18370 
When the EDC system becomes available, the Investigator must transcribe the information from the paper forms  into the EDC system. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 73 of 90
   
    
 
 
  
    If there is need for urgent consultation, the Investigator is to contact the RMO,  
MD, PhD . If the RMO cannot be reached, the Investigator may contact the Call Center as 
described in  Section 5.3.  
10.2 Follow -up Reporting by the Investigator  
The AE CRF completed initially must be updated within 24 hours after the Investigator has 
become aware of any new relevant information concerning the SAE (e.g., outcome, precise description of medical history, results of the investigation). All relevant information must be included directly in the AE CRF and the appropriate Safety Complementary Information CRFs . 
An e -mail alert will be sent automatically to the GP V Department and to the CRA. Copies of 
documents (e.g., medical records, discharge summary, autopsy) may be requested by the GPV Department.  
The anonymity of the subject must always be respected when forwarding this information. 
10.3 Reporting of SAEs Occurring After a Subject Has Completed the Study  
Any SAE that occurs after a subject has completed the study but that is likely to be related to the 
investigational product(s), other products (e.g., a benefit vaccine), or to the experiment must also be reported as soon as possible. In such a case, the reporting procedure to be followed is identical 
to that described in Section 10.1. 
10.4 Assessment of Causality  
The causal relationship between the SAE and the product administered will be evaluated by the 
Investigator as described  in Section 9.1.1.3.6. 
Following this, the Sponsor’s Pharmacovigilance (PV) Global Safety Expert will also assess the 
causal relationship to the product, based on the available information and current medical knowledge. 
The causal relationship to study procedures will be also assessed in the CRB. 
The decision to modify or discontinue the study may be made after mutual agreement between the 
Sponsor and the Investigators. 
10.5 Reporting SAEs to Health Authorities and IECs  / IRBs  
The Sponsor will inform the relevant health authorities of any reportable SAEs according to the 
local regulatory requirements. Reporting to the health authorities will be according to the 
Sponsor’s standard operating procedures. 
The Sponsor’s RMO , MD, PhD will notify the Investigators in writing of the 
occurrence of any reportable SAEs. The Investigators / Sponsor will be responsible for informing 
the IECs or IRBs that reviewed the study protocol.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 74 of 90

   
    
 
 
  
    11 Data Collection and Management  
11.1 Data Collection and CRB  Completion 
Individual diary cards, specifically designed for this study by the Sponsor and provided to the 
study sites, will be given to study participants for the recording of daily safety information as 
described in  Section 9.1.1.3. These diary cards will include prelisted terms and intensity scales 
(see Table 9.1  and Table 9.2) as well as areas for free text to capture additional safety information 
or other relevant details. Parents / guardians will also be provided with rulers for measuring the 
size of injection site reactions, and with standard digital thermometers for measuring daily temperatures. To ensure consistency of reporting, the study sites will instruct parents / guardians 
on how to correctly use these tools.  
The 6 -month follow-up will be done by interviewing subjects ’ parents / guardians  over the 
telephone using a questionnaire to capture MAAEs,  SAEs a nd AESIs , if applicable. A memory 
aid will  be provided to the subjects’ parents / guardians at the preceding study visit to help them 
record information on events occurring between this visit and the 6-month follow-up. Relevant information will be transcri bed into the AE CRF. Any SAEs captured during this 6-
month follow-up period will be reported and followed-up as per the normal process for reporting 
SAEs.  
At specified intervals, the Investigator or an authorized designee will interview the parents / 
guardians to collect the information recorded in the diary card, and will attempt to clarify 
anything that is incomplete or unclear. All clinical study information gathered by the study site 
will be reported electronically by the Investigator or authorized designee using a web -based CRB. 
(Any information that was not documented in the diary card will first be captured in the source document and then reported electronically.) The CRB has been designed specifically for this 
study under the responsibility of the Sponsor, using a validated Electronic Records / Electronic Signature-compliant platform (21 CFR Part 11). 
To ensure the correct and consistent completion of the CRBs, the Sponsor or authorized 
representative will provide all necessary tools, instruction s, and training to all site staff involved 
in data entry prior to study  start. Additional instructional documents such as training manuals and 
completion instructions will be provided to assist with data entry during the course of the study. Upon completion of training, each user requiring access to the EDC system will be issued a 
unique username and password. In the event of a change in study personnel, each newly assigned individual will receive a unique username and password; the username and password of a previous user may not be reissued. If any study personnel leave the study, the Investigator is 
responsible for informing the Sponsor immediately so that their access is deactivated. An audit 
trail will be initiated in the EDC system at the time of the first data entry to track all modifications 
and ensure database integrity. 
The Investigator is responsible for the timeliness, completeness, and accuracy of the information 
in the CRBs ; must provide explanations for all missing information; and must sign th e CRB using 
an e- signature.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 75 of 90
   
    
 
 
  
    11.2 Data Management  
Management of SAE Data 
During the study, SAE data (reported on the AE and Safety Complementary Information CRFs) 
will be integrated into the Sponsor’s centralized GPV database upon receipt of these forms and 
after a duplicate check. Each case will be assigned a case identification number. Each case will be 
assessed by the case management platform or its delegate before being reported to the relevant authorities as necessary. The a ssessment of related cases wi ll be done in collaboration with the PV 
Global Safety Expert and the RMO. Follow-up information concerning a completed case will be entered into the GP V database, and a new version of the case will be created.  
The information from  the GP V database cases will be reconciled with that in the clinical database.  
Management of Clinical Data  
Clinical data, defined as all data reported in the CRB , will be handled by the Sponsor’s Clinical 
Data Management (CDM) platform or authorized representative.  
During the study, clinical data reported in the CRBs will be integrated into the clinical database under the responsibility of the Sanofi Pasteur CDM platform. Data monitoring at the sites and quality control in the form of computerized logic and / or consistency checks w ill be 
systematically applied to detect errors or omissions. In addition, data reviews may be performed several times by the Sponsor’s staff in the course of the study. Any questions pertaining to the reported clinical  data will be submitted to the I nvesti gator for resolution using the EDC system. 
Each step of this process will be monitored through the implementation of individual passwords to maintain appropriate database access and to ensure database integrity.  
After integration of all corrections in the complete set of data, and after the SAE information available from CDM and the GP V Department has been reconciled, the database will be released for 
statistical analysis.  
11.3 Data Review  
A review of the data is anticipated through the data review process led b y Data Management 
before database lock. The safety of the investigational product will be continuously monitored by 
the Sponsor. Periodic safety data review will be performed by the Sponsor’s SMT.  
12 Statistical Methods and Determination of Sample Size 
12.1 Statistical Methods  
Clinical data will be analyzed under the responsibility of the Biostatistics Platform of the Sponsor.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 76 of 90
   
    
 
 
  
    A statistical analysis plan (SAP) will be written and peer reviewed before any analyses. In 
accordance with the protocol, the SAP will describe all analyses to be performed under the 
responsibility of the Sponsor and all the conventions to be taken. 
12.1.1 Hypotheses and Statistical Methods for the Objectives  
12.1.1.1 Hypotheses  
No hypotheses will be tested. Descriptive statistics will be presented.  
12.1.1.2 Statistical Methods  
Safety analysis will include but not be limited to the following: 
• The number and percentage of subjects reporting any solicited injection site reactions and 
solicited systemic reactions occurring from D0 to D07 after each vaccination will be 
summarized by study group for intensity, time of onset period, days of occurrence, and action taken. 
• Immediate unsolicited systemic AEs and unsolicited AEs occurring up to D30 after each 
vaccination will be summarized.  
• The number and percentage of subjects reporting any unsolicited non- serious AEs will be 
summarized by study group, intensity, time of onset period, duration, and by MedDRA 
preferred term and system organ class (SOC), as well as by relationship to the study vaccine.  
• The number and percentage of subjects reporting at least one of any MAAEs will be summarized throughout the trial.  
• The number and percentage of subjects reporting at least one of any SAEs will be summarized 
by study group, seriousness criterion, outcome, and by MedDRA preferred term and SOC, as 
well as by relationship to the study vaccine. 
• The number and percentage of subjects reporting at least one of any AESIs will be 
summarized throughout the t rial. 
• Exact (Clopper-Pearson) 2- sided 95% confidence intervals (CIs) will be calcula ted for the 
percentages.  (56) 
12.2 Analysis Sets  
Six analysis sets will be used: the Overall Safety Analysis Set for any dose (SafAS), Safety  
Analysis Set for vaccination  1 (SafAS1), Safety Analysis Set for vaccination 2 (SafAS2), Safety 
Analysis Set for vaccination 3 (SafAS3), Safety Analysis Set for vaccination 4 (SafAS4), and 
Safety Analysis Set 5 for all 4-dose vaccinati ons (SafAS5). 
12.2.1 Full Analysis Set  
Not applicable to this study. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 77 of 90
   
    
 
 
  
    12.2.2 Safety Analysis Set 
The SafAS is defined as those subjects who have received at least 1 dose of the study vaccine (s) a 
and have any safety data available. Specific safety analysis will be define d and used after each 
vaccination. Safety analysis after all 4-dose vaccinations will also be conducted as well . 
All subjects will have their safety analyzed after each dose according to the vaccine they actually 
received , after any dose, and after all 4 doses according to the vaccine received at the first dose.  
Safety data recorded for a vaccine received out of the protocol design will be excluded from the 
analysis (and listed separately).  
12.2.2.1 Overall Safety Analysis Set for Any Dose 
The over all SafAS  is defined as those subjects who have received at least one dose of the study 
vaccines and have any safety data available. All subjects will have their safety analyzed after any dose according to the vaccine received at the first dose.  
Safety da ta recorded for a vaccine received out of the protocol design will be excluded from the 
analysis (and listed separately).  
12.2.2.2 Safety Analysis Set for Vaccination at 2 Months of Age 
The SafAS 1 is defined as those subjects who have received the study vaccine at Visit 1 around 
2 months of age and have any safety data available. All subjects will have their safety analyzed after the Visit 1 dose according to the vaccine they actually received at V isit 1.  
Safety data recorded for a vaccine received out of the protocol design at Visit 1 will be excluded 
from the analysis (and listed separately).  
12.2.2.3 Safety Analysis Set for Vaccination at 4 Months of Age 
The SafAS2  is defined as those subjects who have received the study vaccine at Visit 2 around 
4 months of age and have any safety data available. All subjects will have their safety analyzed after this dose according to the vaccine they actually received at that visit.  
Safety data recorded for a vaccine received out of the protocol design at Visit 2 will be exclud ed 
from the analysis (and listed separately).  
12.2.2.4 Safety Analysis Set for Vaccination at 6 Months of Age 
The SafAS3  is defined as those subjects who have received the study vaccine at Visit 3 at around 
6 months of age and have any safety data available. All subjects will have their safety analyzed after this dose according to the vaccine they actually received at this visit.  
                                                 
a     A study vaccine is any vaccine that is administered as part of the study, including the investigational product 
(MenACYW conjugate vaccine), the control vaccine (Menveo), and the routine vaccines .  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 78 of 90
   
    
 
 
  
    Safety data recorded for a vaccine received out of the protocol design at Visit 3 will be excluded 
from the analysis (and listed separatel y). 
12.2.2.5 Safety Analysis Set for Vaccination at 12 Months of Age 
The SafAS4 is defined as those subjects who have received the study vaccine at Visit 4 at around 
12 months of age and have any safety data available. All subjects will have their safety analyzed 
after this dose according to the vaccine they actually received at that visit.  
Safety data recorded for a vaccine received out of the protocol design at Visit 4 will be excluded  
from the analysis (and listed separately).  
12.2.2.6 Safety Analysis Set for all 4-dose Vaccinations 
The SafAS5  is defined  as those subjects who have received all 4 doses of the study vaccine 
(3 doses in infancy and 1 dose in the second year of life at 12 months of age) and have any safety 
data available. All 4-dose vaccinations received in a series should be either all MenACYW 
conjugate vaccine or all MENVEO®. 
Safety data recorded for subjects not receiving all 4 dose s of MenACYW or MENVEO® will be 
excluded from the analysis (and lis ted separately).  
12.2.3 Per-Protocol Analysis Set  
Not applicable to this study. 
12.2.4 Populations Used in Analyses 
The safety analysis will be performed on the Safety Analysis Sets SafAS, and SafAS1 through 
SafAS5.  
12.3 Handling of Missing Data and Outliers 
12.3.1 Safety  
No replacement will be done. 
12.3.2 Immunogenicity  
No immunogenicity data will be collected. 12.3.3 Efficacy  
No efficacy data will be collected.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 79 of 90
   
    
 
 
  
    12.4 Interim  / Preliminary  Analysis 
No interim / preliminary  analyses are planned.  
12.5 Determination of Sample Size and Power Calculation  
The sample size of this study was chosen to provide safety data; it is not intended for the purposes 
of hypothesis testing. No formal sample size calculation is performed. 
Though there are no statistically powered hypotheses, the overall study cohort of 3080 subjects 
will provide a probability of approximately 95% of observing any AE with a true incidence of 
0.15%. In the treatment arm with 2310 subjects, there is a probability of approximately 95% of 
observing any AE with a true incidence of 0.2%. 
13 Ethical and Legal Issues and Investigator / Sponsor Responsibilities  
13.1 Ethical Conduct of the Study / Good Clinical Practice  
The conduct of this study  will be consistent with the standards established by the Declaration of 
Helsinki and compliant with the ICH guidelines for GCP as well as with all local and  / or national 
regulations and directives.  
13.2 Source Data and Source Documents 
“Source data” are the data contained in source documents. Source documents are original documents or certified copies, and include, but are not limited to, diary cards, medical and hospital records, screening logs, informed consent / assent forms, telephone contact logs, and 
worksheets. The purpose of study source documents is to document the existence of subjects and to substantiate the integrity of the study  data collected. Investigators must maintain source 
documents so that they are accurate, complete, legible, and up to date. 
For missing or discrepant data on a diary card, the study coordinator will obtain verbal cla rification  
from the subject, enter the response into the “I nvestigator’s comment ” page of the diary card, and 
transfer the information to the CRB. The subject pre -screening  log should list all individuals contacted by the Investigators to 
participate in the study, regardless of the outcome.  
The Investigator must print
a any electronic records on an ongoing basis, sign and date them 
immediately after creation, and keep the printouts on file as source documents that can be verified 
by the Sponsor or an inspector against the electronic records. Any subsequent changes of an 
                                                 
a  Unless the electronic medical records are managed by validated computerized systems th at are compliant with US 
21 CFR Part 11, in which case they are acceptable on their own.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 80 of 90
   
    
 
 
  
    electronic record require the record to be re -printed, dated (with an indication of the date of 
change), and signed. Such records must also be kept together with the original printed copy. 
Good Documentation Practice should be followed by the Investigator and the site staff managing 
source documents.  
13.3 Confidentiality of Data , Data Protection  and Access to Subject Records 
Prior to initiation of the study, the Investigator will sign a fully executed confidentiality agreement with Sanofi Pasteur. In the event a subject’s medical records are not at the investigational site, it is the responsibility of the Investigator, to obtain those records if needed. 
All personal data collected related to subjects, Investigators, or any person involved in the study, 
which may be included in the Sponsor’s databases, shall be treated in compliance with all 
applicable laws and regulations, including the Global Data Protection Regulation (GDPR). Data collected must be adequate, relevant and not excessive, in relation to the purposes for which they are collected. Each category of data must be properly justified and in line with the study objective. 
Subjects’ race and ethnicity will be collected in this study because these data are required by the 
FDA in the US (57). 
Subjects will be assigned a unique identifier by the Sponsor. Any subject records or datasets that are transferred to the Sponsor will contain the identifier only; subject names or any information that would make the subject identifiable will not be transferred. 
The subject must be informed that his/her personal study-related data will be used by the Sponsor 
in accordance with local data protection law. The level of disclosure must also be explained to the subject. 
The subject must be informed that his/her medical records may be examined by C linical Quality 
Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate 
IRB/IEC members, and by inspectors from regulatory authorities. 
When archiving or processing personal data pertaining to the Investigator and/or to th e subjects, 
the Sponsor shall take all appropriate measures to safeguard and prevent access to this data by any 
unauthorized third party. 
13.4 Monitoring, Auditing, and Archiving  
13.4.1 Monitoring  
Before the start of the study  (i.e., before the inclusion of the first subject) in the first center the 
Investigators and the Sponsor’s staff or a representative will meet at the site -initiation visit to 
discuss the study protocol and the detailed study procedures. Emphasis will be placed on inclusion 
and exclusion criteria, visit timing, safety procedures, informed consent procedures, SAE reporting procedures, CRB  completion, and the handling of products. The Sponsor’s staff  or a 
representative will ensure and document that all material to be used during the study has been 
received at the site; and that the study investigator team and local Sponsor/delegate staff have 
been properly informed about the study , GCP and regulatory requirements, and the Sponsor’s 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 81 of 90
   
    
 
 
  
    procedures. Specific training sessions for the study  inves tigator team and the CRAs on these 
topics may be performed as necessary, and should be documented. 
The following instruction manuals will be provided: the CRF Completion Instructions  for entering 
data into the CRB, and the Operating Guidelines for detailed study procedures such as the product 
management. After the start of the study , the Sponsor’s staff or a representative will be in regular contact with 
the investigational team through telephone calls and regular follow-up visits. The Investigator or 
delegate must be available for these visits, and must allow the Sponsor /delegate staff direct access 
to subject medical files and CRBs . During these visits, the Sponsor/delegate staff will:  
• Evaluate the quality of the study progress (adherence to protocol and a ny study- specific 
guidelines, quality of data collection and document completion, signature of consent forms, occurrence of SAEs, product management, cold-chain monitoring, archiving) 
• Source-verify completed CRBs and any corresponding answered queries 
• Dete rmine the number of complete or ongoing issues identified at monitoring visits (e.g., 
protocol deviations , SAEs) . Any identified problems will be discussed with the Investigator, 
and corrective or preventive actions will be determined, as appropriate. 
After all protocol procedures have been completed and the data have been entered into the CRB, 
the Investigator must still be available to answer any queries forwarded by the Sponsor. All data-related queries must be completed prior to database lock. 
At the en d of the study, a close -out visit will be performed to ensure that:  
• The center has all the documents necessary for archiving  
• All unused materials and products have been either destroyed or returned to the Sponsor 
13.4.2 Audits and Inspections  
A quality assurance audit may be performed at any time by the Sponsor’s Clinical Quality 
Assessment  department ( CQA) or by independent auditors to verify that the study has been 
conducted according to the protocol, GCP and ICH requirements, and other appli cable 
regulations. An inspection may be conducted by regulatory authorities. The Investigator must 
allow direct access to study  documents during these inspections and audits. 
13.4.3 Archiving  
The Investigator must keep all study documents after the completion or discontinuation of the 
study, whatever the nature of the investigational center (private practice, hospital, or institution), for as long as required by applicable laws and regulations. In the absence of any applicable laws or regulations, study documents will be kept at a minimum for the duration indicated on the 
Clinical Trial Agreement (CTA). In no event, should study personnel destroy or permit the destruction of any study documents upon less than 90 days advance written notification to the Sponsor. In addition, study  documents should continue to be stored, at Sponsor's sole expense, in 
the event that the Sponsor requests in writing that such storage continues for a period of time that exceeds that required by any applicable law or regulation  or the CTA . The Investigator will 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 82 of 90
   
    
 
 
  
    inform Sanofi Pasteur of any address change or if they will no longer be able to house the study 
documents. 
Archived data may be held on electronic records, provided that a back-up exists and that a hard 
copy can be obtained if required. The protocol, documentation, approvals, and all other documents related to the study will be kept by the Sponsor in the Trial Master File (TMF). Data on AEs are included in the TMF. All data and documents will be made available if requested by relevan t authorities.  
13.5 Financial Contract and Insurance Coverage  
A CTA will be signed by all the parties involved in the study’s performance, if relevant. The 
Sponsor has an insurance policy to cover any liabilities that may arise from use of the product and 
/ or the study  protocol. 
13.6 Stipends for Participation  
The subject’s parent / guardian may be provided with a stipend according to local practice to compensate for the time and travel required for study visits and procedures. 
13.7 Publication Policy  
Data derived from this study are the exclusive property of Sanofi Pasteur . Any publication or 
presentation related to the study must be submitted to Sanofi Pasteur  for review before submission 
of the manuscript. After publication of the results of the study, any participating center may publish or otherwise use its own data provided that any publication of data from the study  gives 
recognition to the study group. In addition, Sanofi Pasteur  shall be offered an association with all 
such publications, it being understood that Sanofi Pasteur  is entitled to refuse the association.  
Sanofi Pasteur must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study at least 90  days prior to submission for publication / 
presentation. Any information identified by Sanofi Pasteur  as confidential must be deleted prior to 
submission, it being understood that the results of this study are not to be considered confidential. 
Sanofi Pasteur’s review can be expedited to meet publication guidelines. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 83 of 90
   
    
 
 
  
    14 Reference List  
 
1.  Harrison LH, Granoff DM, Pollard AJ. Meningococcal capsular group A, C, W, and Y 
conjugate vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. 
Vaccines. 7th ed. Philadelphia (PA): Elsevier;2018:619-43. 
2. Borrow R, Alarcón P, Carlos J, et al. The Global Meningococcal Initiative: global 
epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16(4):313-28. 
3. Harrison OB, Claus H, Jiang Y, et a l. Description and nomenclature of Neisseria 
meningitidis capsule locus. Emerg Infect Dis. 2013;19(4):566-73. 
4. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr 
Infect Dis J. 2004;23(12 Supp):S274-9. 
5. Kvalsvig AJ, Unsworth DJ. The immunopathogenesis of meningococcal disease. J Clin 
Pathol. 2003;56(6):417- 22. 
6. Sidikou F, Djibo S, Taha MK, et al. Polymerase chain reaction assay and bacterial 
meningitis surveillance in remote areas, Niger. Emerg Infect Dis. 2003;9(11):1486-8. 
7. World Health Organization. Meningococcal disease, serogroup W135 (update). WER. 
2001;76(28):213-4. 
8. Sáfadi MA, O'Ryan M, Valenzuela Bravo MT, et al. The current situation of 
meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations. Vaccine. 2015;33(48):6529-36. 
9. Ceyhan M, Yildirim I, Balmer P, et al. A prospective study of etiology of childhood acute 
bacterial meningitis, Turkey. Emerg Infect Dis. 2008;14(7):1089-96. 
10. Kilic A, Urwin R, Li H, Saracli MA, Stratton CW, Tang YW. Clonal spread of serogroup 
W135 meningococcal disease in Turkey. J Clin Microbiol. 2006;44(1)222-4. 
11. Shao Z, Zhou H, Gao Y, et al. Neisseria meningitidis serogroup W135, China. Emerg 
Infect Dis. 2010;16(2):348-9. 
12. Zhou H, Liu W, Xu L, et al. Spr ead of Neisseria meningitidis serogroup W clone, China. 
Emerg Infect Dis. 2013;19(9):1496-9. 
13. Efron AM, Sorhouet C, Salcedo C, Abad R, Regueira M, Vasquez JA. W135 invasive 
meningococcal strains spreading in South America: significant increase in incidence rate 
in Argentina. J Clin Microbiol. 2009;47(6):1979-80. 
14. Weidlich L, Baethgen LF, Mayer LW, et al. High prevalence of Neisseria meningitidis 
hypervirulent lineages and emergence of W135:P1.5,2:ST-11 clone in southern Brazil. J Infect. 2008;57(4):324- 31. 
15. Barroso DE, Rebelo MC. Recognition of the epidemiological significance of Neisseria 
meningitidis capsular serogroup W135 in the Rio de Janeiro region, Brazil. Mem Inst Oswaldo Crus. 2007;102(6):773-5. 
16. Boisier P, Nicholas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence 
of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007;44(5):657-63. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 84 of 90
   
    
 
 
  
    17. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of 
meningococcal disease in the United States, 1992 -1996. J Infect Dis. 1999;180(6):1894-
901. 
18. Canadian Immunization Committee and Public Health Agency of Canada. Advice for 
consideration of quadrivalent (A, C, Y, W135) meningococcal conjugate vaccine, for use 
by provinces and territories. CCDR. 2010;36(S2):1-35. 
19. Bröker M, Jacobsson S, Kuusi M, et al. Meningococcal serogroup Y emergence in Europe: 
update 2011. Hum Vaccin Immunother. 2012;8(12):1907-11. 
20. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease 
epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-91. 
21. National Foundation for Infectious Diseases. Addressing the challenges of serogroup B 
meningococcal disease outbreaks on campuses: A report by the National Fo undation for 
Infectious Diseases. May 2014. Available from:  http://www.nfid.org/meningococcal- b. 
Accessed 05 July 2017.  
22. Centers for Disease Control and Prevention. Interim g uidance for control of serogroup B 
meningococcal disease outbreaks in organizational settings. Available from: http://www.cdc.gov/meningococcal/downloads/interim-guidance.pdf. Accessed 05 July 2017. 
23. European Centre for Disease Prevention and Control. Surve illance of invasive bacterial 
diseases in Europe 2008/2009. Stockholm: ECDC; 2011. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/1107_SUR_IBD_2008-09.pdf. Accessed on 12 July 2017. 
24. Public Health England. Increase in endemic meningococcal group W (MenW) ST-11 
complex associated with severe invasive disease in England and Wales. Health Protection Weekly Report. Vol 8 No 41 Published on: 24 October 2014. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/367588/hpr4114.pdf. Accessed 05 July 2017. 
25. Ladhani S, Lucidarme J, Newbold LS, et al. Investigations into an increase in reported 
meningococcal serogroup Y disease in England and Wales in 2007-9. Presented at: The European Meningococcal Disease Society (EMGM). 11th EMGM Meeting, 18 -20 May 
2011. Ljubljana Slovenia. Poster 035:107. 
26. Törös B, Thulin Hedberg S, Jacobsson S, Fredlund H, Olcén P, Mölling P. Surveillance of 
invasive Neisseria meningitidis with a serogroup Y update, Sweden 2010 to 2012. Euro Surveill. 2014;19(42):pii=20940. 
27. Thulin Hedberg S, Törös B, Fredlund H, Olcén P, Mölling P. Genetic characterisation of 
the emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveill. 2011;16(23):pii=19885. 
28. Caugant DA, Løvoll Ø, Blystad H. Meningococcal disease in Norway, 2009-2010: 
emergence of serogroup Y. Presented at: The European Meningococcal Disease Society (EMGM). 11th EMGM Meeting, 18-20 May 2011. Ljubljana Slovenia. Poster 040:117. 
29. Vainio A, Toropainen M, Kuusi M, Virolainen A. Characteristics of invasive 
meningococcal serogroup Y isolates in Finland, 1995-2010. Presented at: The European 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 85 of 90
   
    
 
 
  
    Meningococcal Disease Society (EMGM). 11th EMGM Meeting, 18 -20 May 2011. 
Ljubljana Slovenia. Poster 037:110.  
30. Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) 
Report: Neisseria meningitidis, 2013. Available from: http://www.cdc.gov/abcs/reports -
findings/survreports/mening13.html. Accessed 20 July 2017. 
31. Centers for Disease C ontrol and Prevention. Meningococcal disease. In: Hamborsky J, 
Kroger A, Wolfe S, eds. Epidemiology and Prevention of Vaccine- Preventable Diseases. 
13th ed. Washington D.C. Public Health Foundation, 2015:231-45. 
32. Centers for Disease Control and Prevention. Update: Guillain -Barré syndrome among 
recipients of Menactra meningococcal conjugate vaccine --United States, June 2005-
September 2006. MMWR. 2006; 55(41):1120-4. 
33. Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain- Barré syndrome after 
meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012;21(12):1350-8. 
34. Institute of Medicine. Diphtheria toxoid, tetanus toxoid, and acellular pertussis-containing 
vaccines. In: Adverse effects of vaccines: evidence and causality. Washington, DC: The 
National Academies Press;2012:557-8. https://doi.org/10.17226/13164. 
35. Institute of Medicine. Diphtheria and tetanus toxoids. In: Adverse events associated with 
childhood vaccines: evidence bearing on causality. Washington, DC. The National Academies Press; 1994:67 -117. https://doi.org/10.17226/2138. 
36. Centers for Disease Control and Prevention. General recommendations on immunization: 
recommendations of the Advisory Committee on Immunization Practices (ACIP):MMWR. 2011;60(2):1-60. 
37. Menveo [package insert]. GSK Vaccines, Srl, Bellaria -Rosia 53018, Sovicille (SI), Italy. 
Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Menveo/pdf/MENVEO.PDF. Accessed 25 October 2018. 
38. Centers for Disease Control and Prevention. Healthcare Providers/Professionals. 
https://www.cdc.gov/vaccines/hcp/admin/administer-vaccines.html. Updated 22 August 2017. Accessed 21 September 2017. 
39. Kroger AT, Duc hin J, Vázquez M. General Best Practice Guidelines for Immunization. 
Best Practices Guidance of the  Advisory Committee on Immunization Practices (ACIP). Available from www.cdc.gov/vaccines/hcp/acip -recs/general -recs/downloads/general-
recs.pdf. Accessed 3 May 2018. 
40. Marin M, Güris Dalya, Chaves SS, et al, Recommendations of the Advisory Committee on 
Immunization Practices (ACIP), Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC. Available from https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm. Accessed 3 May 2018.  
41. Centers for Disease Control and Prevention Epidemiology and Prevention of Vaccine-
Preventable Diseases, 13th Edition, April 2015. Available at https://www.cdc.gov/vaccines/pubs/pinkbook/varicella.html. Accessed 3 May 2018.  
42. Pentacel [package insert]. Sanofi Pasteur Ltd, Toronto, Ontario, Canada. Available from: 
https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm109810.pdf. Accessed 06 July 2017. 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 86 of 90
   
    
 
 
  
    43. PREVNAR 13® [package insert]. Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc, 
Philadelphia, PA, USA. Available from: 
https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm201669.pdf. Accessed on 06 July 2017. 
44. RotaTeq® [package insert]. Merck Sharp  & Dohme Corp., a subsidiary of Merck & Co., 
Inc., Whitehouse Station, NJ, USA. Available from: https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm142288.pdf. Accessed on 06 July 2017. 
45. ENGERIX-B® [package insert]. GlaxoSmithKline Biologicals 441 Rixensart, Belgium. 
Available from: https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm224503.pdf. Accessed on 06 July 2017. 
46. M-M-R® II [package insert]. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., 
Inc., Whitehouse Station, NJ, USA. Available from: https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm123789.pdf. Accessed on 06 July 2017. 
47. VARIVAX® [package insert]. Merck Sharp & Dohme Corp., a subsidiary of Merck & 
Co., Inc., Whitehouse Station, NJ, USA. Available from: https://www.merck.com/product/usa/pi_circulars/v/varivax/varivax_pi.pdf. Accessed on 25 October 2018. 
48. Bonhoeffer J, Menkes J, Gold MS, et al. Generalized convulsive seizure as an adverse 
event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004;22:557-62.  
49. Marcy SM, Kohl KS, Dagan R, et al. Fever as an adverse event following immunization: 
case definition and guidelines of data collection, analysis and presentation. Vaccine. 2004; 22:551-6. 
50. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long- term 
management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever,  Endocarditis, and Kawasaki Disease, Council on 
Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114(6):1708-33. 
51. Centers for Disease Control and Prevention. Kawasaki syndrome case report 2003. 
Available from: http://www.cdc .gov/kawasaki/pdf/ks_case_report- fillable.pdf. Accessed 
01 February 2018. 
52. Phuong LK, Bonetto C, Buttery J, et al and Brighton Collaboration Kawasaki Disease 
Working Group. Kawasaki disease and immunisation: standardised case definition & guidelines for dat a collection, analysis. Vaccine. 2016;34(15):6582-96. 
53. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain- Barré syndrome and Fisher syndrome: case 
definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(3):599 -612. 
54. Wise RP, Bonhoeffer J, Beeler J, et al. Thrombocytopenia: case definition and guidelines 
for collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5717-24.  
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 87 of 90
   
    
 
 
  
    55. Chu YW, Korb J, Sakamoto M. Idiopathic thrombocytopenic purpura. Pediatr Rev. 
2000;21(3):95-104. 
56. Newcombe RG. Two -sided confidence intervals for the single proportion: comparison of 
seven methods. Stat Med. 1998;17:857-72.  
57. Guidance for Industry and Food and Drug Administration Staff. Collection of race and 
ethnicity data in clinical trials. Available from: 
https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126396.pdf 
 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 88 of 90
   
    
 
 
  
    15 Signature Page  
 
Sanofi Pasteur 
Confidential/Proprietary Information 
MET41
395 – MenACYW Conjugate Vaccine
Protocol Version 4.0
Page 89 of 90